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ABSTRACT
STUDY OF ABC MEMBRANE TRANSPORTERS IN SINGLE LIVE CELLS
Preeyaporn Songkiatisak
Old Dominion University, 2018
Director: Dr. Xiao-Hong Nancy Xu

The multidrug ATP-binding cassette (ABC) membrane transporters (efflux
pumps) are found in both prokaryotes and eukaryotes and they can extrude diverse
structurally unrelated substrates, such as antibiotics and chemotherapeutic agents out
of the cells. The efflux pumps are responsible for multidrug resistance (MDR) and the
failure of numerous treatments in infections and cancers. All ABC membrane
transporters share a common modular topology containing two transmembrane
domains (TMDs) and two nucleotide binding domains (NBDs). The underlying molecular
mechanisms regarding how the similar structural ABC membrane transporters could
selectively extrude a wide variety of substrates and cause MDR, are not yet fully
understood. Radioisotopes and fluorophores have been widely used as probes to study
efflux kinetics of multidrug membrane transporters in bulk cells which could have
masked interesting rare events from individual cells. Moreover, radioisotopes and
fluorophores do not process size-dependent physicochemical properties, making them
unsuitable to serve as various sized substrates for the study of efflux function of the
ABC transporter. In this dissertation, we focus on the development of three different
sized single silver nanoparticles (Ag NPs) to serve as both drug nanocarriers and
imaging probes to study size-dependent efflux function of ABC membrane transporters
in single live cells (e.g., Escherichia coli) in situ in real time. We synthesized and
characterized Ag NPs with diameters of 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm,
functionalized them with a monolayer of 11-amino-1-undecanethiol (AUT) to prepare
AgMUNH2 NPs (control nanocarriers). We then covalently linked the AgMUNH2 NPs
with ofloxacin (Oflx) to prepare AgMUNH-Oflx NPs (antibiotic drug nanocarriers) with
conjugation ratios of 8.6x102, 9.4x103, and 6.5x105 Oflx molecules per NP, respectively.
We studied inhibitory effects of these antibiotic drug nanocarriers against E. coli and
found size-dependent inhibitory effects in which the same amount of Oflx carried by the

largest nanocarriers exhibited the highest inhibitory effects, and the smallest
nanocarriers exhibited the lowest inhibitory effects. The AgMUNH2 NPs did not show
significant inhibitory effects on cell growth. Furthermore, we used Ag NP-based
nanocarriers as imaging probes to study efflux function of multidrug ABC membrane
transporters in single live E. coli cells, because Ag NPs process distinctive sizedependent photostable plasmonic optical properties. We found that the accumulation
rates of nanocarriers highly depended on the NP concentration, the presence of
ATPase pump inhibitor, and the types and sizes of nanocarriers. Interestingly, the ABC
membrane transporters extrude AgMUNH-Oflx NPs more effectively and rapidly than
AgMUNH2 NPs indicating that efflux pumps could be equipped with a sensing
machinery to detect, recognize and extrude toxic substrates (e.g., antibiotics). Notably,
the cells could extrude the smaller nanocarriers more effectively, leading to the least
inhibitory effects. Therefore, the smaller drug nanocarriers could serve as excellent
imaging probes to study the efflux function while the larger nanocarriers serve as
powerful drug delivery vehicles. This study demonstrates the possibility of developing
optimal-sized nanocarriers to achieve the maximum drug efficacy and potentially
avoiding MDR.
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NOMENCLATURE
ε

Extinction coefficient

ΔABM

Pseudomonas aeruginosa mutant strain with no expression of
MexAB-OprM pumps

λmax

Peak wavelength

°C

Degree Celsius

µm

Micrometer

µM

Micromolar

µL

Microliter

ABC

ATP-binding cassette

Ag NPs

Silver Nanoparticles

Ag

Silver

AgMUNH2

Silver nanoparticle functionalized with 11-amino undecanethiol

AgMUNH-Oflx

Silver nanoparticle functionalized with 11-amino undecanethiol
and conjugated with ofloxacin

ATP

Adenosine triphosphate

Au

Gold

AUT

11-amino-1-undecanethiol hydrochloride

C

Concentration

14C

Radioactive isotope of carbon

CCD

Charged coupled device

Cryo-EM

Cryo-electron microscopy

DSB

Double-strand break

DFOMS

Dark-field optical microscopy and spectroscopy

DI

De-ionized

viii

DLS

Dynamic light scattering

DNA

Deoxyribonucleic acid

EDC

1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride

FWHM

Full-width-at-half-maximum

h

Hour

3H

Tritium, a radioactive isotope of hydrogen

H2O2

Hydrogen peroxide

HRTEM

High-resolution transmission electron microscopy

LB

Luria broth

LPS

Lipopolysaccharide

LSPR

Localized surface plasmonic resonance

MΩ

Megaohms

min

Minutes

mL

Milliliter

ms

Millisecond

MIC50

Minimum inhibitory concentration at 50%

MDR

Multidrug resistance

nM

Nanomolar

nm

Nanometer

ns

Nanosecond

NaBH4

Sodium borohydride

s-NHS

N-hydroxysulfosuccinimide

NBD

Nucleotide binding domain

NPs

Nanoparticles

OD

Optical Density

ix

Oflx

Ofloxacin

p

Probability value

pM

Picomolar

PBS

Phosphate buffer saline

Pgp

P-glycoprotein

PI

Propidium iodide

PVP

Polyvinyl pyrrolidine

rcf

relative centrifugal force

R

Ratio

rpm

Revolutions per minute

s

Seconds

SMNOBS

Single molecular nanoparticle optical biosensor

TEM

Transmission electron microscopy

TMD

Transmembrane domain

UV-vis

Ultraviolet-visible

WT

Wild type
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CHAPTER I

OVERVIEW

The ATP-binding cassette (ABC) membrane transporters are highly conserved
proteins found in both prokaryotes and eukaryotes.1-3 They use the energy of ATP
binding and hydrolysis to translocate a large number of structurally and functionally
unrelated substrates across biological membrane.1-3 Multidrug ABC transporters (efflux
pumps) can extrude antibiotics out of bacterial cells and chemotherapeutic agents from
cancer cells resulting in multidrug resistance (MDR) and the failure of numerous
treatments of infections and cancers.2-4

MDR is responsible for the creation of

superbugs and an urgent need of better drugs against pathogenic bacteria.5-6 Multidrug
membrane transporters have been extensively studied as a target aiming to overcome
MDR and improve the efficacy of therapeutic drugs.7
All ABC transporters share a similar modular topology including two
transmembrane domain (TMD) and two nucleotide binding domain (NBD). 1, 3, 7-8 In spite
of extensive studies over decades, the molecular basis of MDR and efflux mechanisms
of multidrug membrane transporters, for example how the similar structural membrane
transporters could extrude diverse structurally unrelated substrates, remain not yet fully
understood.5 Conventional methods for the study of transport efflux kinetics in bulk
bacterial cells include the use of radioisotopes (14C and 3H) or fluorophores (ethidium
bromide and Hoechst dye) as probes to measure accumulations of substrates in the
cells.9-12 Study of the accumulation kinetics of bulk cells could have masked crucial rare
events as individual cells act differently and their efflux kinetics are unsynchronized,
emphasizing the importance of probing efflux kinetics of individual membrane
transporters in single live cells in real time.13-14 Moreover, single radioisotope or
fluorophore are unable to measure sizes of substrates and membrane transporters as
they

lack

distinctive

size-dependent

physicochemical

properties.

Thus,

these

conventional probes are not suitable to serve as various size-dependent pump
The journal guide for this dissertation is ACS Nano 2018, 12, 2138-2150.
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substrates for the study of efflux function of single membrane transporter in single live
cells in real time.
The technological leap of nanomaterials provides the most promising strategies
to overcome MDR and circumvent many side effects and toxicity from high doses of
antibiotics.15-17 Nanomaterials process unique physiochemical properties, particularly
minuscule sizes and high surface-to-volume ratios.18-19 These distinctive features make
nanomaterials outstanding among other candidates as drug delivery vehicles to
increase the drug payloads and enhance local drug doses resulting in therapeutic
improvement.20-21 Among nanomaterials, noble metal nanoparticles (e.g., Ag NPs and
Au NPs) are the most interesting due to their unique plasmonic optical and surface
properties.17, 22
Nobel metal nanoparticles (e.g., Ag NPs) process distinctive plasmonic
properties, which highly depend on their sizes, shapes, dielectric constant, and
surrounding environments.23-24 Single Ag NPs have high Rayleigh scattering enables us
to image and characterize them under illumination of halogen lamps using dark-field
optical microscopy and spectroscopy (DFOMS).14, 25-27 We have demonstrated that we
can use superior size-dependent LSPR and photostable single Ag NPs as optical
probes to study the size-dependent efflux kinetics of multidrug membrane transporters
in single live cells in real time.9,

13-14, 28-29

We have systematically studied the

dependence of the accumulation of substrates and efflux function on the sizes, charges,
chemicals, and bacterial strains of Gram-positive bacteria (BmrA in Bacillus subtilis)9, 13,
29-30

and Gram-negative bacteria (MexAB-OprM in Pseudomonas aeruginosa)14,

31-33

using bare and surface-functionalized NPs to mimic various sizes of antibiotics (drugs)
with different surface properties (drug functional groups).
In this dissertation, we firstly used Ag NPs as powerful drug delivery vehicles
because of their small sizes and high surface-to-volume ratio properties. We
synthesized

and

characterized

three

different

sized

Ag

NP-based

antibiotic

nanocarriers, aiming to study the dependence of the therapeutic effects of antibiotics
(e.g., ofloxacin, Oflx) on the size of nanocarriers in a bacterial model (Escherichia coli).
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We further used single antibiotic drug nanocarriers as excellent imaging probes to study
efflux function of multidrug ABC membrane transporters. These studies would offer new
insights into the mechanisms of MDR of multidrug ABC membrane transporters and the
rational design of nanocarriers to improve drug efficacy and evade MDR.
This dissertation contains six chapters. In Chapter I, we provide a brief overview
of the research background and significant findings of this dissertation research, and an
outline the contents of each individual chapter.
In Chapter II, we developed antibiotic drug nanocarriers from different sized bare
Ag NPs and then studied the dependence of their inhibitory effects against bacterial
cells upon the dose of antibiotics and the size of nanocarriers. We aimed to (i) design
antibiotic drug nanocarriers to achieve high efficacy, importantly to combat MDR and (ii)
rationally develop biocompatible antibiotic drug nanocarriers to study efflux function of
single multidrug membrane transporters in live bacterial cells. In this study, we
synthesized and characterized three different sized bare Ag NPs (2.4 ± 0.7, 13.0 ± 3.1,
and 92.6 ± 4.4 nm) and functionalized these NPs with a monolayer of 11-amino-1undecanethiol hydrochloride (AUT) to prepare AgMUNH2 NPs (control nanocarriers),
and then covalently conjugated the amine group of the AgMUNH2 NPs with the carboxyl
group of an antibiotic (ofloxacin, Oflx) to produce antibiotic drug nanocarriers
(AgMUNH-Oflx NPs). We determined the amount of conjugated Oflx molecules on each
single NP (the conjugation ratios) of 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm as 8.6x10 2,
9.4x103, and 6.5x105 Oflx molecules/NP, respectively. We studied the dependence of
inhibitory effects of free Oflx and conjugated Oflx attached on the surface of the
nanocarriers on the dose of Oflx and the size of nanocarriers in E. coli and found that
the inhibitory effects Oflx significantly depend on the dose of Oflx and the size of
nanocarriers. The equal amount of Oflx carried by the large nanocarriers (13.0 ± 3.1
and 92.6 ± 4.4 nm) are much more toxic than free Oflx inhibiting cell growth and causing
extensive cellular filamentation whereas surprisingly those delivered by the smaller
nanocarriers are less toxic than free Oflx, as illustrated in Figure 1. The MIC50 of free
Oflx and the antibiotic nanocarriers with a diameter of 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ±
4.4 nm are 0.144, 0.314, 0.081 and 0.026 µM, respectively. Moreover, our control

4

experiments showed that the AgMUNH2 NPs (control nanocarriers) are biocompatible
and do not exhibit significant inhibitory effects on the cell growth. Thus, the results
suggest that an optimal size of the nanocarriers is required to create maximum
inhibitory effects against pathogenic bacteria in which the same amount of Oflx
generates a substantially higher bactericidal potency when it is carried and delivered by
the larger nanocarriers.

5

Figure 1. Schematic illustration of size-dependent inhibitory effects of antibiotic
drug nanocarriers against E. coli using DFOMS.34
The inhibitory effects of free Oflx and conjugated Oflx attached on the surface of the
nanocarriers depend on the dose of Oflx and the size of nanocarriers in E. coli. The
largest antibiotic drug nanocarriers (92.6 ± 4.4 nm) show the highest inhibitory effects
with the lowest MIC50 (0.026 ± 0.003 μM) of Oflx while the smallest antibiotic drug
nanocarriers (2.4 ± 0.7 nm) exhibit the lowest bactericidal inhibitory with the highest
MIC50 (0.314 ± 0.010 μM) of Oflx against E. coli. The larger antibiotic drug nanocarriers
demonstrate higher efficacy of ofloxacin to target DNA gyrase during cell replication as
the cells treated with conjugated Oflx carried by the larger nanocarriers show less
numbers of cells and extensive cellular filamentation. The densely loaded Oflx
molecules (multivalence) could enhance their binding affinity to the targets and the
higher drug payload could raise local drug concentrations and their bactericidal effects.
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In Chapter III, we used we used 2.4 ± 0.7 nm AgMUNH-Oflx NPs (the smallest
antibiotic drug nanocarriers) and the same sized AgMUNH2 NPs (control nanocarriers)
to probe efflux kinetics of ABC (MsbA) membrane transporters of single live E coli cells.
We demonstrate that we can use LSPR spectra of single AgMUNH-Oflx NPs and
AgMUNH2 NPs to identify and track transports of single NPs in and out of single cells
over time using DFOMS. We found the high dependence of the accumulation of
intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs upon a presence of a pump
(ATPase) inhibitor (25 µM orthovanadate) and the concentration of NPs (0.7 and 1.4
nM), suggesting that the NPs enter the cells via passive diffusion which are driven by
concentration gradient across the cellular membrane and are extruded out by multidrug
ABC membrane transporter. Interestingly, we found that the accumulation of AgMUNH2
NPs is higher than those of AgMUNH-Oflx NPs in single live cells, suggesting the efflux
pumps can extrude noxious substrates (e.g., conjugated Oflx) more effectively and
rapidly out of the cells as illustrated in Figure 2. This provides powerful evidence that
multidrug membrane transporters could have a sensing machinery to selectively detect,
recognize toxic substances (e.g., antibiotics and anticancer drugs), and then extrude
them out as cellular defense mechanisms.

7

Figure 2. Schematic illustration of study of substrate-dependent efflux function of
multidrug ABC (MsbA) membrane transporters in single live E. coli cells using 2.4
± 0.7 nm drug nanocarrier optical probes.35
The accumulation of intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs depend upon
a presence of a pump (ATPase) inhibitor (25 μM orthovanadate), the concentration of
NPs and the type of NPs. The accumulation of the AgMUNH2 NPs is twice higher than
those of the AgMUNH-Oflx NPs in single live cells, suggesting substrate-dependent
efflux kinetics of MsbA. The efflux pumps can extrude noxious substrates (e.g.,
AgMUNH-Oflx NPs) more effectively and rapidly out of the cells than biocompatible
substrates (e.g., AgMUNH2 NPs). This provides evidence that the multidrug ABC
membrane transporters might have a sensing machinery to selectively detect, recognize
toxic substances (e.g., antibiotics and anticancer drugs), and then extrude them out as
cellular defense mechanisms.
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In Chapter IV, we used 13.0 ± 3.1 nm AgMUNH-Oflx NPs (the slightly larger
antibiotic drug nanocarriers) and AgMUNH2 NPs (control nanocarriers) to probe efflux
kinetics of ABC (MsbA) membrane transporters of single live E coli cells under dark-field
microscopy. We found that the accumulation rates increase with the NP concentrations,
suggesting passive diffusion could be the primary mechanism for the NPs enter into the
cells. Interestingly, we found that the number of intracellular AgMUNH2 NPs are far
more than those of AgMUNH-Oflx NPs as presented in Figure 3. The pump inhibitor can
only cause an increase of the accumulation rate of intracellular AgMUNH-Oflx NPs but
not AgMUNH2 NPs. These results confirm the dependence of efflux function of MsbA
membrane transporters on types of substrates and the efflux pumps effectively extrude
harmful substances, as reported previously in Chapter III.

9

Figure 3. Schematic illustration of study of efflux mechanisms of multidrug ABC
(MsbA) membrane transporters in single live E. coli cells using 13.0 ± 3.1 nm sizedependent plasmonic drug nanocarrier optical probes.36
The accumulation of intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs depend upon
a presence of a pump (ATPase) inhibitor (25 μM orthovanadate), the concentration of
NPs and the type of NPs. The NPs enter the cells through passive diffusion and are
extruded out of the cells by the multidrug ABC membrane transporters. The
accumulation of the AgMUNH2 NPs is 24 times higher than those of the AgMUNH-Oflx
NPs in single live cells, suggesting substrate-dependent efflux kinetics of MsbA and the
efflux pumps can effectively extrude harmful substances.
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In Chapter V, we studied efflux kinetics of ABC (MsbA) membrane transporters of
single live E coli cells using the largest antibiotic drug nanocarriers (92.6 ± 4.4 nm
AgMUNH-Oflx NPs) and the same sized control nanocarriers (AgMUNH2 NPs). We
found that the accumulation rates of intracellular NPs and efflux kinetics of MsbA
membrane transporters highly depend on the concentration of NPs, suggesting that
such large NPs could passively diffuse into the cells. Moreover, orthovanadate could
interrupt efflux function of MsbA membrane transporters leading to the increase of
accumulation rates of intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs. Interestingly,
similar to the smaller drug nanocarriers (2.4 ± 0.7 and 13.0 ± 3.1 nm), we found that the
accumulation rates of intracellular AgMUNH2 NPs in the presence and absence of
orthovanadate are higher than those of the AgMUNH-Oflx NPs, confirming that the
efflux pump could detect conjugated Oflx molecules on the antibiotic drug nanocarriers
and extrude them out more effectively than the control nanocarriers. Notably, we found
size-dependent accumulation rates of intracellular AgMUNH-Oflx NPs. As illustrated in
Figure 4, the number of intracellular NPs of the larger NPs (92.6 ± 4.4 nm) at 3.7 pM is
lower than those of the smaller NPs (2.4 ± 0.7 nm and 13.0 ± 3.1 nm) at 1.4 nM possibly
due to their low concentration gradient across the cellular membrane and/or their low
membrane permeability. If we increase the concentration of the larger NPs (92.6 ± 4.4
nm) to 1.4 nM (378 times), the number of intracellular NPs and their accumulation rates
could have been much higher than the smaller NPs, suggesting that they could be least
effectively extruded out the cells.
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Figure 4. Schematic illustration of study of substrate- and size-dependent efflux
function of multidrug ABC (MsbA) membrane transporters in single live E. coli
cells using 92.6 ± 4.4 nm drug nanocarrier optical probes.37
The accumulation of intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs depend upon
a presence of a pump (ATPase) inhibitor (25 μM orthovanadate), the concentration of
NPs and the type of NPs. The NPs enter the cells through passive diffusion and are
extruded out of the cells by the multidrug ABC membrane transporters. The
accumulation of the AgMUNH2 NPs is twice higher than those of the AgMUNH-Oflx NPs
in single live cells, suggesting substrate-dependent efflux kinetics of MsbA and the
efflux pumps can effectively extrude harmful substances. The smaller nanocarriers
could be effectively extrude out of the cells by the multidrug ABC membrane
transporters more effectively than the larger nanocarriers, and therefore, they are less
toxic than the larger nanocarriers.
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In Chapter VI, we summarized our research findings that previously described in
the preceding chapters, underscored the significance of this research, and discussed
the possible future research goals.
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CHAPTER II

STUDY OF SIZE-DEPENDENT INHIBITORY EFFECTS OF ANTIBIOTIC DRUG
NANOCARRIERS AGAINST ESCHERICHIA COLI

INTRODUCTION
Antibiotics have been used to treat infectious diseases for many years. Due to
over-consumption and inappropriate use of these drugs, resistance to antibiotics has
become increasingly widespread and posed significant challenges for infectious
treatments.15 MDR is responsible for the development of antibiotic resistance causing
numerous impacts including higher doses of drugs, additional treatments and an urgent
need of novel antibiotics.15 The MDR phenomena are mainly associated with a robust
array of membrane transporters of efflux pumps that extrude a wide variety of
substrates including amino acids, ions, lipids and various drugs.5-6 Multidrug membrane
transporters have been extensively studied as a target aiming to overcome MDR and
improve the efficacy of therapeutic drugs.7 Unfortunately, molecular mechanisms of
MDR and functions of membrane transporters remain ambiguous after decades of
research.5
Escherichia coli (E. coli) is an opportunistic Gram-negative bacteria that can
cause severe diarrhea, urinary tract infections and respiratory illness. 38-39 There are
several membrane transporters associated with efflux systems in E. coli.7 For instance,
the MsbA is an essential ATP-binding cassette transporter protein for cell growth and is
closely related to mammalian MDR proteins (Pgp, ABCB1, MDR1).6,

40-41

In bacterial

MsbA, a TMD is fused to an NBD in a half-transporter that then homodimerizes to form
the full transporter

5, 20

MsbA is a poly-specific transporter which can recognize and

transport a wide spectrum of drug molecules.1, 10, 41 .
The use of nanomaterials provides the most promising strategies to overcome
MDR and circumvent many side effects and toxicity from high doses of antibiotics.15-17
Nanomaterials possess such unique physiochemical properties, particularly minuscule
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sizes and high surface-to-volume ratios.18-19 Reduction of the size of the nanomaterials
leads to a dramatic increase in the surface area relative to their volume, giving facile
surface functionalization with various biological and drug molecules.18 Nanocarriers
promote drug binding affinity and increase the local drug payload resulting in enhanced
therapeutic efficacy.20-21 Although various nanomaterials with different designs, sizes
and shapes have been extensively used as drug nanocarriers 15-16, systematical studies
to understand their dependence of therapeutic effects and underlying molecular
mechanisms upon their physiochemical properties, such as sizes are still elusive.
Furthermore, recent studies mainly use biodegradable nanoparticles, such as liposome
but only few studies focus on using noble metal NPs as nanocarriers to treat bacterial
infection.16
Noble metal NPs (e.g. Ag and Au) have been proven to be versatile and widely
used materials in biomedical applications, such as drug delivery and nanobiosensors26,
42-43

In addition to a large surface-to-volume ratio, Ag NPs possess distinctive size-

dependent photostable plasmonic optical properties enable us to image and determine
the sizes of single NPs at the nanometer (nm) resolution in real time using dark-field
optical microscopy and spectroscopy (DFOMS).25 We have used the size-dependent
localized surface plasma resonance (LSPR) spectra (color) of single NPs to study the
sizes of NPs as they transported in and out of single live cells and thus determine the
pore sizes of the membrane transporters.9,

14

Moreover, We have developed single

molecule nanoparticle optical biosensors (SMNOBS) from Ag NPs to probe important
molecular events, such as cell apoptosis at a single cell resolution in real time.26, 42
In this study, we have synthesized, purified and characterized three different
sized stable Ag NPs nanocarriers (2.4 ± 0.7, 13.0 ± 3.1 and 92.6 ± 4.4 nm). We have
quantitatively studied dose and size dependent bactericidal effects of these antibiotic
drug nanocarriers against E. coli, aiming to determine the dependence of the inhibitory
effects of conjugated Oflx upon the size of nanocarriers. Single Ag NPs can serve as
powerful drug delivery vehicles and excellent imaging probes, which allow us to
investigate roles of different sized nanocarriers not only in boosting drug efficacy but
also in efflux function of multidrug membrane transporters. These will guide us to the
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rational design of optimally sized nanocarriers that can enhance drug binding affinity
and increase the local drug payload concentrations at the target sites to achieve the
highest drug efficacy and, more importantly overcome MDR.

RESULTS AND DISCUSSION
Synthesis and Characterization of Three Different Sized Ag NPs
We have synthesized and purified three different sized Ag NPs, as described in
Methods and as we reported previously.25-26,

43-45

Representative TEM images (Figure

5A: a-c) and histograms of size distribution (Figure 5B: a-c) of three different NP
samples show nearly spherical shaped NPs with diameters of (2.4 ± 0.7), (13.0 ± 3.1)
and (92.6 ± 4.4) nm, respectively.46 Notably, the shapes of the smallest NPs are the
closest to the spherical. In contrast, the shapes of the largest NPs are polygonal (the
least spherical). The diameters of oval and irregular shaped NPs are determined by
averaging the length and width of the NPs.
We characterized the plasmonic absorption and scattering of Ag NP solutions
using UV-vis absorption spectroscopy.46 UV-vis absorption spectra of three different
sized NPs with diameters of (2.4 ± 0.7), (13.0 ± 3.1) and (92.6 ± 4.4) nm show the peak
wavelength with full width at half maximum, λmax (FWHM), at 392 (57), 395 (59) and 450
(182) nm, respectively. We did not observe any shoulder peak for NPs with diameters
of either (2.4 ± 0.7) or (13.0 ± 3.1) nm, further demonstrating that they are nearly
spherical. In contrast, we observed one shoulder peak wavelengths at 390 nm for the
diameter of NPs of (92.6 ± 4.4) nm, which are most likely attributed to the in-plane
quadrupole resonance of the NPs generated by transverse collective oscillation of the
surface electrons between edges of the NPs. Notably, the TEM images of the NPs
(Figure 5A: c) indeed show that they are polygonal with sharp edges. 46
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Figure 5. Characterization of sizes, shapes and plasmonic optical properties of
three different sized Ag NPs.46
(A) HRTEM images of single Ag NPs and (B) histograms of their size distributions show
nearly spherical shaped NPs with average diameters of (a) 2.4 ± 0.7, (b) 13.0 ± 3.1 and
(c) 92.6 ± 4.4 nm. (C) UV-vis spectra of the NPs in DI water show the peak absorption
(full width at half maximum), λmax (FWHM), at: (a) 392 (57), (b) 395 (59), and (c) 450 nm
with a shoulder peak of 390 nm, respectively.
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Synthesis and Characterization of Antibiotic Nanocarriers (AgMUNH-Oflx NPs)
We functionalized the well purified and characterized Ag NPs with a monolayer of
11-amino-1-undecanethiol (AUT) by replacing citrate molecules electrostatically
adsorbed on the surface of the NPs with AUT via the interaction of thiol groups of AUT
with the NPs, to prepare AgMUNH2 NPs, as presented in Material and Method and
Figure 6. We washed the AgMUNH2 NPs thoroughly with nanopure water to remove
excess AUT using centrifugation. We then covalently conjugated the amine groups of
each sized AgMUNH2 NPs with the carboxyl group of ofloxacin (Oflx) via a peptide bond
using a two-step method via EDC and s-NHS as mediators to prepare antibiotic
nanocarriers (AgMUNH-Oflx NPs), as illustrated in Figure 6.46
We purified the drug nanocarriers (AgMUNH-Oflx NPs) by thoroughly washing
them with deionized (DI) water, and characterized the conjugation ratios of Oflx
molecules to the NPs using UV-vis absorption spectroscopy, as shown in Figure 7 and
Table 1.46 The absorption spectrum of 2.4 ± 0.7 nm Ag NPs (Figure 7A: a) shows a
plasmonic absorption peak wavelength of 390 nm with a FWHM of 55 nm. After the
surface of the NPs was functionalized with a monolayer of AUT, the refractivity of the
NPs decreased and their dielectric constant increased, leading to a red-shifted and
broader plasmonic absorption spectrum. Thus, the plasmonic absorption spectrum of
AgMUNH2 NPs (Figure 7A: b) shows a peak wavelength of 413 nm and a FWHM of 132
nm. Upon conjugation of Oflx with the AgMUNH2 NPs, we observed both the distinctive
absorption peak wavelengths of Oflx at 288 and 331 nm and the plasmonic peak
absorption of the NPs at 416 nm for the nanocarriers (AgMUNH-Oflx NPs). We
subtracted the absorption spectrum of AgMUNH2 NPs from that of AgMUNH-Oflx NPs
and determined the concentration of Oflx covalently attached onto the nanocarriers
using the absorbance at 288 nm. We used the plasmonic peak absorbance of NPs in
the same nanocarriers to determine the concentration of NPs. We divided the Oflx
concentration of the nanocarrier by the NP concentration of the same nanocarrier
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A

B

C

Figure 6. Schematic illustration of synthesis of three different sized antibiotic
drug nanocarriers (Adapted from Ref 46).46
Functionalizing Ag NPs with monolayer of 11-amino-1-undecanethiol using interaction
of its thiol groups (-SH) with the surface of Ag NPs with diameters of (A) 2.4 ± 0.7, (B)
13.0 ± 3.1 and (C) 92.6 ± 4.4 nm to synthesize AgMUNH2 NPs. The amine groups of
AgMUNH2 conjugate with the carboxyl groups of ofloxacin via a peptide bond using
EDC and sulfo-NHS as mediators to prepare AgMUNH-Oflx NPs called as antibiotic
drug nanocarriers.
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Figure 7. Characterization of conjugation ratios of Oflx molecules with NPs for
three different sized Ag NPs using UV-vis absorption spectroscopy.46
(A) UV-vis absorption spectra of: (a) 2.4 ± 0.7 nm Ag NPs, (b) AgMUNH 2 NPs and (c)
AgMUNH-Oflx NPs show the plasmonic absorption peak wavelength (λmax) of NPs at
392, 413 and 416 nm, respectively. (B) UV-vis absorption spectra of: (a) 13.0 ± 3.1 nm
Ag NPs, (b) AgMUNH2 NPs and (c) AgMUNH-Oflx NPs show the plasmonic absorption
λmax of NPs at 394, 414 and 418 nm, respectively. (C) UV-vis absorption spectra of: (a)
92.6 ± 4.4 nm Ag NPs, (b) AgMUNH2 NPs and (c) AgMUNH-Oflx NPs show the
plasmonic absorption λmax of NPs at 450, 453 and 486 nm, respectively. Note that Oflx
signature absorption λmax at 288 and 331 nm were observed in (c) only for all three
sized nanocarriers in (A-C), showing the conjugation of Oflx with the NPs.
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solution to quantitatively characterize the conjugation ratio of Oflx molecules to NPs,
showing 8.6 × 102 Oflx molecules/NP for the 2.4 ± 0.7 nm Ag NPs. Using a closepacked model with the footprint of each AUT molecule of 0.214 × 0.214 nm2 on the
surface of the NP,43 we found that the smooth surface area of a perfectly spherical NP
with a diameter of 2.4 nm could only accommodate 395 Oflx molecules/NP. The 2-fold
higher payload of 8.6 × 102 Oflx molecules/NP could be attributed to the rough surface
and irregular shape of the NPs.46
The absorption spectrum of the 13.0 ± 3.1 nm Ag NPs (Figure 7B: a) shows a
plasmonic absorption peak wavelength at 399 nm and a FWHM of 58 nm. After their
surface was functionalized with a monolayer of AUT, their plasmonic absorption
spectrum (Figure 7B: b) red-shifted and showed a peak wavelength of 413 nm and a
FWHM of 132 nm. After the AgMUNH2 NPs were conjugated with Oflx, the plasmonic
absorption spectrum of AgMUNH-Oflx NPs (nanocarriers) exhibited both the distinctive
absorption peak wavelengths of Oflx at 288 and 331 nm as well as the plasmonic peak
absorption of NPs at 418 nm for the nanocarriers (AgMUNH-Oflx NPs). Using the same
approaches as described above, we quantitatively characterized the conjugation ratio of
Oflx molecules to NPs as 9.4 × 103 Oflx molecules/NP for the 13.0 ± 3.1 nm NPs, which
is nearly equal to the maximum number of AUT molecules (1.2 × 10 4 molecules) that
could be closely packed on the surface of a spherical NP with a diameter of 13 nm, as
determined by the close-packed model.46
The absorption spectrum of the 92.6 ± 4.4 nm Ag NPs (Figure 7C: a) shows a
plasmonic absorption peak wavelength at 450 nm. After their surface was functionalized
with a monolayer of AUT, the peak wavelength of the plasmonic absorption spectrum
red-shifted to 453 nm (Figure 7C: b). Upon conjugation of the AgMUNH 2 NPs with Oflx,
the plasmonic absorption spectrum of AgMUNH-Oflx NPs exhibited both the distinctive
absorption peak wavelengths of Oflx at 288 and 331 nm as well as a further red-shifted
plasmonic peak absorption of the NPs to 500 nm. Using the same approaches
described above, we quantitatively characterized the conjugation ratio of Oflx to the NPs
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as 6.5 × 105 Oflx molecules/NP for the 92.6 ± 4.4 nm NPs, which is approximately equal
to the maximum number of AUT molecules (5.9 × 10 5 molecules) that could be closely
packed on the surface of a perfectly spherical NP with a diameter of 92.6 nm, as
determined by the close-packed model.46

Table 1. Determination of Conjugation Ratios of Ofloxacin (Oflx) Molecules per NP
for Three Different Sized Drug Nanocarriers. 46

a Plasmonic

Diameter of NPs
(nm)

CNPsa

R Oflx per NPc

(nM)

COflxb
(µM)

2.4 ± 0.7

50

43.2

8.6x102

13.0 ± 3.1

3.3

31.1

9.4 x103

92.6 ± 4.4

0.030

19.4

6.5 x105

absorbance of drug nanocarriers (AgMUNH-Oflx NPs) at λmax of 416, 418,

486 nm was used to determine the concentration of 2.4 ± 0.7; 13.0 ± 3.1 and 92.6 ± 4.4
nm NPs, respectively.
b

COflx was determined by subtracting UV-vis spectra of AgMUNH2 NPs from that of

AgMUNH-Oflx NPs, and dividing the peak absorbance of the subtracted UV-vis spectra
at 288 nm by molar absorptivity (ε288 nm) of Oflx, 7.8x103 M-1 cm-1
c

Conjugation ratio of the number of Oflx molecules per NP was calculated by dividing

the concentration of Oflx with concentration of NPs for the same solution of AgMUNHOflx NPs for 2.4 ± 0.7; 13.0 ± 3.1 and 92.6 ± 4.4 nm NPs, respectively.
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Study of Stability of Drug Nanocarriers (AgMUNH-Oflx NPs) in Cell Culture
Medium
In order to study the dependence of the inhibitory effects of these antibiotic
nanocarriers against E. coli on the sizes of NPs and doses of antibiotic, it is crucial that
the nanocarriers remain stable (non-aggregated) in cell culture medium and that their
sizes and doses remain unchanged over the entire duration of the cell culture
experiment. If the nanocarriers aggregate in the cell culture medium, then their sizes
and doses would change over time, making a study of their size and dose dependent
inhibitory effects unreliable.
Therefore, we first characterized the stability (non-aggregation) of each size of
drug nanocarriers (AgMUNH-Oflx NPs) in a commonly used standard LB medium (1%
tryptone, 0.5% yeast extract, and 0.5% NaCl in DI water, pH = 7.2) over 24 h using
UV−vis absorption spectra. Unfortunately, none of the nanocarriers at the desired
concentration were stable in this standard medium.46
We then reduced the concentration of NaCl to 0.1% and characterized the
stability (non-aggregation) of the drug nanocarriers in the modified medium (1%
tryptone, 0.5% yeast extract, and 0.1% NaCl in DI water, pH = 7.2) over 24 h using
UV−vis absorption spectroscopy. The results in Figure 8 show that the absorption
spectra of the nanocarriers remain unchanged over 24 h, indicating that the
nanocarriers with Ag NP diameters of 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm and
concentrations of 6.0 nM, 0.8 nM, and 7 pM were stable (non-aggregated) in the
modified medium over 24 h, respectively.46
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Figure 8. Characterization of the stability (non-aggregation) of three sized
antibiotic nanocarriers (AgMUNH-Oflx NPs) in the modified LB medium using UVvis absorption spectroscopy.46
The UV-vis absorption spectra of 6 nM, 0.8 nM and 7 pM of AgMUNH-Oflx NPs for the
Ag NPs with diameters of: (A) 2.4 ± 0.7, (B) 13.0 ± 3.1 and (C) 92.6 ± 4.4 nm, in the
modified LB medium at (a) 0 and (b) 24 h, remain essentially unchanged over time,
which indicates that the nanocarriers were stable (non-aggregated) in the medium over
24 h, respectively.
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Characterization of Suitability of the Modified LB Medium for Cell Culture
We previously found that the antibiotic drug nanocarriers were unstable in the
standard LB medium (1% tryptone, 0.5% yeast extract and 0.5% NaCl in DI water, pH =
7.2) but they were stable (non-aggregation) in the modified LB medium (1% tryptone,
0.5% yeast extract and 0.1% NaCl in DI water, pH = 7.2).46 Therefore, we studied cell
growth of E. coli (MsbA) strain in the modified LB medium to ensure that it was suitable
for culturing healthy cells as the standard LB medium. We pre-cultured the cells in the
standard LB medium for 12 h. We then cultured the pre-culture cells in the standard and
the modified LB and measure the cell growth over time by measuring optical density at
600 nm (OD600 nm) every hour. The growth curves of the cells cultured in the standard
LB medium (Figure 9A) and the cells cultured in the modified LB medium (Figure 9B)
are similar indicating that the modified LB medium is well suited to culture the cells.
We then characterized the viability of cells cultured in the standard and the
modified medium over 16 h via LIVE/DEAD BacLight assay. Representative images of
the cells cultured in the standard LB medium (Figure 10A) and the modified LB medium
(Figure 10B) show SYTO9 green fluorescence (Figure 10A, B: b) but not propidium
iodide (PI) red fluorescence demonstrating that cells are viable. As the cells cultured in
the modified LB medium show more than 99% viability (Figure 10C), the modified LB
medium can be used to culture the cells.
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Figure 9. Characterization of growth kinetics of the live cells cultured in standard
and modified LB medium.
The cellular growth curves of E. coli (MsbA) in (A) standard and (B) modified LB
medium over time show that the growth rates of the cells in either medium are nearly
identical, which indicates that the modified LB medium is well suited to culture the cells.
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Figure 10. Characterization of viability of E. coli (MsbA) cells cultured in standard
and modified LB medium using LIVE/DEAD BacLight assay.
Optical image (a) and fluorescence images (b) of single E. coli (MsbA) cultured in
medium over 16 h, and suspended in the PBS buffer and assayed using LIVE/DEAD
BacLight assay. The cells emitted the green fluorescence (λ

max

= 525 nm) of SYTO9

indicating viable cells (C) Plot of the percent of the live cells (live cells divided by the
total number of cells) cultured in (a) standard and (b) modified LB medium show that
more than 99% of the cells (MsbA) are viable, which further indicates that the modified
LB medium is well suitable to culture the cells. Minimum 900 cells were assayed. The
scale bar in (A) is 5 µm.
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In addition, we characterized the efflux pump function of MsbA in live cells by
probing the dependent accumulation of intracellular fluorescence dye (Hoechst 33342)
using time-course fluorescence intensity. The Hoechst 33342 dye is a well-known
substrate of MsbA (ABC) membrane transporters and has been used to for efflux
function studies.10-11 The dye emits weak fluorescence intensity in aqueous solution but
its intensity dramatically increases (up to 10 times) once it internalizes into the cells and
intercalates with DNA.47 Therefore, Hoechst 33342 dye is suitable for monitoring
intracellular accumulation of the dye and for characterization of the efflux function of
multidrug membrane transporters of live cells in real time. The results in Figure 11
demonstrated the fluorescence intensity of Hoechst 33342 dye (0.5 µM) incubated with
the cells cultured in the standard LB medium (Figure 11C) and the modified LB medium
(Figure 11D) gradually increased and remain stable over time. We further studied
effects of a pump (ATPase) inhibitor, orthovanadate,48-49 on the efflux pump function.
The cells cultured in the standard LB medium (Figure 11A) and the modified LB medium
(Figure 11B) with a presence of orthovanadate (25 µM) showed higher accumulation
rates of the dye than in their absence. Altogether, the cells cultured in modified LB
medium exhibited relatively the same efflux pump function of MsbA as those in the
standard LB medium demonstrating that the modified LB medium well suited to culture
healthy cells.
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Figure 11. Characterization of accumulations and efflux kinetics of the Hoechst
33342 for live cells cultured in standard and modified LB medium.
Time-dependent fluorescence intensity of Hoechst 33342 (0.5 µM) incubated with the
cells (OD

600 nm

= 0.1 in PBS buffer, pH 7.2): MsbA cells cultured in standard (A) and

modified (B) LB medium in the presence of 25 μM orthovanadate and MsbA cells
cultured in standard (C) and modified (D) LB medium in the absence of orthovanadate.
The cells cultured in standard (A and C) and modified (B and D) LB medium show
similar accumulation and efflux kinetics, which demonstrates that the modified LB
medium is well suitable to culture the cells for the study of accumulation and efflux
kinetics of MsbA.
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Study of Size and Dose Dependence of Inhibitory Effects of Antibiotic Drug
Nanocarriers
We cultured the cells (104 pre-cultured cells) in the modified LB medium
containing a dilution series of free drug Oflx, each given sized antibiotic drug
nanocarriers (AgMUNH-Oflx NPs) and the corresponding size of AgMUNH 2 NPs (no
conjugated Oflx, control experiment) in test tubes. We then incubated the cells with
vigorous shaking (200 rpm, 37 ºC) over 18 h.
The dilution series consist of 0, 0.045, 0.09, 0.18, 0.38 and 0.68 µM of free drug
Oflx (Figure 12A: a-f) or the conjugated Oflx from the antibiotic drug nanocarriers
(Figure 12B-D: a-e), which corresponded to the concentrations of antibiotic drug
nanocarriers (NP concentrations): (Figure 12B: a-e) 5.21x10-2, 0.104, 0.209, 0.440, and
0.788 nM of NPs with a diameter of 2.4 ± 0.7 nm using the ratio of 8.6x102 Oflx
molecules per NP; (Figure 12C: a-e) 4.77x10-3, 9.54x10-3, 1.91x10-2, 4.03x10-2 and
7.21x10-2 nM for NPs with a diameter of 13.0 ± 3.1 nm using the ratio of 9.4x103 Oflx
molecules per NP; (Figure 12D: a-e) 6.89x10-2, 0.138, 0.276, 0.582 and 1.04 pM for
NPs with a diameter of 92.6 ± 4.4 nm using the ratio of 6.5x105 Oflx molecules per NP.
Moreover, control experiments included the modified LB medium alone (No cells) and
the cells that were cultured at the same time and under the same conditions as
samples, incubated with the modified LB medium containing 0.788 nM, 7.21x10-2 nM
and 1.04 pM AgMUNH2 NPs (in the absence of Oflx) with a diameter of Ag NPs of 2.4 ±
0.7, 13.0 ± 3.1 and 92.6 ± 4.4 nm, respectively (Figure 12B-D: f).
We sampled the cell solutions every 6 h and quantitatively determined the
bacterial cell concentration by measuring OD600 nm in a 96-well plate using a plate reader
(BioTek SynergyHT) equipped with an UV-vis absorption spectral detector. We
subtracted OD600 nm of the NPs or the antibiotic drug nanocarriers from the cell samples
with the NPs or the antibiotic drug nanocarriers to determine the OD 600
concentrations. We plotted OD600

nm

nm

of the cell

of the cell suspension over time and determined

18h as the duration for the cells in the medium alone (control) required to reach
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Figure 12. Study of the concentration and size dependent inhibitory effects of
antibiotic drug nanocarriers (AgMUNH-Oflx NPs) upon the growth of E. coli
(MsbA) cells.
Images of the modified LB-medium cultured with the MsbA cells containing: (A) free
drug Oflx alone at 0, 0.045, 0.09, 0.18, 0.38 and 0.68 μM (a-f); (B) the conjugated Oflx
from antibiotic drug nanocarriers with a diameter of 2.4 ± 0.7 nm at 0.045, 0.09, 0.18,
0.38 and 0.68 μM (a-e); (C) the conjugated Oflx from antibiotic drug nanocarriers with a
diameter of 13.0 ± 3.1 nm at 0.045, 0.09, 0.18, 0.38 and 0.68 μM (a-e); (D) the
conjugated Oflx from antibiotic drug nanocarriers with a diameter of 92.6 ± 4.4 nm at
0.045, 0.09, 0.18, 0.38 and 0.68 μM (a-e). The concentrations of Oflx conjugated onto
the NPs are determined based upon their conjugation ratios. The concentrations of
AgMUNH2 NPs in (f) containing the same concentration of the NPs as those in (e) for
each type of NPs in (B-D) but without carrying Oflx (control experiments for the study of
effects of NPs), respectively.
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confluence and for the cells in the medium with Oflx or drug nanocarriers or NPs to
reach their equilibriums. We used the OD600

nm

of each cell suspension at 18 h to

determine the inhibitory effects of the free drug Oflx and conjugated Oflx as described in
the following.
The plot of normalized OD600

nm

of the cells suspension cultured with free drug

Oflx and the conjugated Oflx with a given sized antibiotic drug nanocarrier at 18 h
(Figure 13) indicates that the inhibitory effects of Oflx significantly depend upon the
dose of Oflx and the size of the antibiotic drug nanocarriers. The control experiments
(Figure 13A-C) of the cells incubated with each size of AgMUNH2 NPs (absence of Oflx,
2.4 ± 0.7, 13.0 ± 3.1 or 92.6 ± 4.4 nm) which consisted of the same concentration of
NPs as those of the highest concentration of the given sized nanocarrier, gave the
same OD600 nm as those cultured in the medium alone. These findings indicate that the
AgMUNH2 NPs do not significantly contribute to inhibitory effects on the growth of MsbA
cells.
On the contrary, the OD600

nm

of the cell suspension incubated with Oflx alone

show the high dose-dependent inhibitory effects of Oflx on the growth. As the
concentration of Oflx increases, OD600

nm

of the cell suspension decreases, indicating

that the number of the cells decreases. By fitting the plot (Figure 13D), we determined
the concentration of Oflx that reduced the cell growth to half and defined it as minimum
inhibitory concentration (MIC50) of Oflx. The MIC50 of free Oflx is 0.144 ± 0.008 µM
(Table 2). Likewise, the results in Figure 13E-G show high dose-dependent inhibitory
effects as the OD600

nm

of the cell suspension decreases when the concentration of

conjugated Oflx increases. Interestingly, the OD600 nm of the cell suspension incubated
with 2.4 ± 0.7 nm drug nanocarriers with the conjugation ratio of 8.6x102 Oflx
molecules/NP decreases less rapidly than those of free Oflx and the other two larger
nanocarriers, giving the MIC50 of 0.314 ± 0.010 µM Oflx (Figure 13E). The MIC50 of 13.0
± 3.1 nm drug nanocarriers with the conjugation ratio of 9.4x103 Oflx molecules/NP is
0.081 ± 0.002 µM Oflx (Figure 13F) which is lower than the MIC50 of free Oflx and 2.4 ±
0.7 nm drug nanocarriers. Notably, the MIC50 of 92.6 ± 4.4 nm drug nanocarriers with
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Figure 13. Study of dose and size dependent inhibitory effects of antibiotic drug
nanocarriers (AgMUNH-Oflx NPs) in E. coli (MsbA) using UV-vis spectroscopy.
Plots of normalized OD600

nm

of the cells cultured for 18 h in the modified LB-medium

containing (A-C) AgMUNH2 NPs (absence of Oflx, control), (D) free drug Oflx, and (E-G)
the conjugated Oflx from antibiotic drug nanocarriers with a diameters of NPs (E) 2.4 ±
0.7, (F) 13.0 ± 3.1 and (G) 92.6 ± 4.4 nm, respectively.

The concentrations of

AgMUNH2 NPs in (A-C) containing the same concentration of the NPs as those carried
the highest Oflx concentrations in (E-G) for each type of NPs but without carrying Oflx
(control experiments for the study of effects of NPs), respectively.

The points are

experimental data and a solid line is generated by fitting of the experimental data with
an equation (y = a*e-bx) as followings: (D) y = 1.12 e-5.57x, R2 = 0.944; (E) y = 1.12 e-2.56x,
R2 = 0.928; (F) y = 1.08 e-9.58x, R2 = 0.941; (G) y = 1.01e-26.7x, R2 = 0.988.
Concentrations of Oflx (MIC50) for free Oflx and Oflx conjugated on a given sized
nanocarrier were determined using the exponential fitting equation at the half of the
maximum of the normalized OD600 nm for each curve, respectively.
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Table 2. Study of Dependence of the MIC of Oflx upon the Size of Nanocarriers
against E. coli (MsbA-WT)
Samples

MIC50 of Oflx (μM) *

Free Oflx alone

0.144 ± 0.008

Nanocarriers (2.4 ± 0.7 nm)

0.314 ± 0.010

Nanocarriers (13.0 ± 3.1 nm)

0.081 ± 0.002

Nanocarriers (92.6 ± 4.4 nm)

0.026 ± 0.003

* The MIC of Oflx for each sample was determined by fitting the experimental data with
the exponential decay (y = a*e-bx, inhibitory effects upon the exponential cell growth) to
determine the parameters (a and b) of a fitting equation with a regression. The equation
was then used to determine the concentration of Oflx at which the cell growth was
inhibited to the half of the cell growth of the blank control experiment, as described in
Figure 13 caption.

the conjugation ratio of 6.5x105 Oflx molecules/NP is 0.026 ± 0.003 µM Oflx (Figure
13G), showing the lowest MIC50 and the highest inhibitory effects among the
nanocarriers and free Oflx. We summarize MIC50 of free Oflx and drug nanocarriers in
Table 2. The results show the significant dependence of inhibitory effects of Oflx upon
the dose of Oflx and the size of nanocarriers.
It is noteworthy that the MIC50 of conjugated Oflx show significant size
dependence. The largest size (92.6 ± 4.4 nm) nanocarriers exhibit the lowest MIC 50 and
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the highest inhibitory effects among the nanocarriers and free drug Oflx. In other words,
the same amount of Oflx molecules loaded and delivered via the largest NPs (92.6 ± 4.4
nm) is the most potent, followed by 13.0 ± 3.1 nm nanocarriers, free Oflx and 2.4 ± 0.7
nm nanocarriers (Table 2). The MIC50 of conjugated Oflx of 2.4 ± 0.7 nm nanocarriers is
2.2 times higher than that of free drug Oflx. In contrast, the MIC 50 of conjugated Oflx of
13.0 ± 3.1 nm and 92.6 ± 4.4 nm nanocarriers are 1.8 times and 5.5 times lower than
that of free Oflx. These findings suggest that the densely loaded Oflx on the larger
nanocarriers could enhance binding affinity with the target (multivalence) and contribute
to higher local drug concentration compared with those Oflx molecules on the smaller
nanocarriers. Notably, the MIC50 of free Oflx and conjugated Oflx in Table 2 indicates
that the inhibitory effects of drug nanocarriers significantly depend on their sizes but not
in a linear manner, which suggests the tradeoff between the distribution of the same
amount of the drugs throughout the cells (pharmacodynamics) and localization of the
same amount of loaded on individual nanocarriers (high affinity) could contribute to their
inhibitory effects. Free drug Oflx and conjugated Oflx on the smaller nanocarriers (2.4 ±
0.7 nm) possibly distribute inside the cells better than the drugs loaded with the larger
nanocarriers (13.0 ± 3.1 nm and 92.6 ± 4.4 nm) while the larger nanocarriers offer the
higher local drug concentration and the better drug binding affinity with the target sites
than the smaller nanocarriers. Considering the combination of drug distribution and
multivalence factors, a critical size of nanocarriers is required to enhance and maximize
antibiotic potency against pathogenic bacterial cells.
Interestingly, the inhibitory effects of free drug ofloxacin and conjugated Oflx in
antibiotic drug nanocarriers against E. coli cells follow the same trend as those against
P. aeruginosa (WT and ΔABM).46 We previously reported that the MIC50 of free drug
Oflx and conjugated Oflx on 2.4 ± 0.7, 13.0 ± 3.1 and 92.6 ± 4.4 nm nanocarriers
against were 0.59 ± 0.16, 1.00 ± 0.07, 0.40 ± 0.06 and 0.11 ± 0.01 µM, respectively.46
For the same amount of Oflx molecules carried and delivered by the largest NPs (92.6 ±
4.4 nm) are the most potent, followed by 13.0 ± 3.1 nm nanocarriers, free drug Oflx, and
2.4 ± 0.7 nm nanocarrier. The MIC50 of Oflx varies in different bacterial strains because
Oflx antibiotic potency could depend upon several factors including the membrane

35

permeability of the drug and the ability of the cells to extrude the drug out of the cells.16,
50

Notably, we have studied efflux function of multidrug ABC (MsbA) membrane

transporters using these three-sized drug nanocarriers as imaging probes and found
that the efflux pumps could extrude all the sized nanocarriers.
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The cells could

extrude the smaller nanocarriers more effectively, leading to the least inhibitory effects.
In contrast, the cells could not extrude the largest nanocarriers out of single live cells as
effectively as smaller NPs. The extrusion of conjugated Oflx of the largest nanocarriers
could affect the MIC50 of the largest nanocarriers the most similar to results from our
previous study.46 These observations emphasize that the inhibitory effects could be
attributed to the interplay among various factors, including multivalence effects, drug
distribution, and extrusion of Oflx molecules.

Filamentation Induced by Ofloxacin in E. coli
Ofloxacin is a broad-spectrum antibiotic in the fluoroquinolone family commonly
used to treat infections of the skin, bladder and urinary tract.51 The molecular target is
DNA gyrase (topoisomerase II) which is a crucial bacterial enzyme catalyzing the
negative supercoiling of double stranded DNA during cell replication resulting in DNA
double-strand breaks (DBSs).51 Processing of DBSs induces the SOS response (DNA
repair mechanism) in E. coli, leading to a cascade of events such as filamentation. 52-54
Generally, -lactam antibiotics are reported to induce filamentous cells initiation by
inhibiting penicillin-binding protein which terminate the formation of the peptidoglycan
network in the bacterial cell wall.52,

55

The fluoroquinolones possibly induce

peptidoglycan degradation causing filamentous cells by partially inactivating D-alanine
carboxypeptidases, enzymes that are suggested to regulate the extent of peptide sidechain cross-linking in peptidoglycan.52, 56
In addition to measuring OD600 nm, we sampled the cells incubated with a series
of free drug Oflx, each given sized antibiotic drug nanocarriers (AgMUNH-Oflx NPs) and
the same size of AgMUNH2 NPs (no conjugated Oflx, control experiment) in test tubes
to image using dark-field microscopy. Representative images of the cells incubated with
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Figure 14. Study of cellular filamentation induced by ofloxacin in single E. coli
(MsbA) cells.
Dark-field optical images of single E. coli (MsbA) cells cultured for 18 h in the modified
LB medium containing (A) 0 and (B-D) 0.045 μM Oflx in antibiotic drug nanocarriers with
diameters of NPs (B) 2.4 ± 0.7, (C) 13.0 ± 3.1 and (D) 92.6 ± 4.4 nm, show that the
inhibitory effects of the antibiotic drug nanocarriers depends upon the sizes of the
nanocarriers. Antibiotic drug nanocarriers attach to the cells and the larger size of the
antibiotic drug nanocarriers demonstrate higher efficacy of ofloxacin to target DNA
gyrase during cell replication as the cells treated with conjugated Oflx carried by the
larger nanocarriers (C and D) showed less numbers of cells and extensive cellular
filamentation. The scale bar is 10 µm.
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(Figure 14A) 0 (control) and (Figure 14B-D) 0.045 μM conjugated Oflx from antibiotic
drug nanocarriers with diameters of NPs (b) 2.4 ± 0.7, (c) 13.0 ± 3.1 and (d) 92.6 ± 4.4
nm, respectively showed that the inhibitory effects of the antibiotic drug nanocarriers
upon the growth of E. coli (MsbA) cells are associated with the sizes of the
nanocarriers. The same amount of Oflx delivered into the cells using the largest
nanocarriers is the most potent since the cells exposed 92.6 ± 4.4 nm antibiotic drug
nanocarriers, vice versa (Figure 14) demonstrate cellular filamentation indicating the
inhibitory action of Oflx.

SUMMARY
We have successfully synthesized, purified and characterized three different
sized Ag NPs with a diameter of 2.4 ± 0.7, 13.0 ± 3.1 and 92.6 ± 4.4 nm, then
functionalized them with a monolayer of MUNH2 to prepare AgMUNH2 NPs and then
covalently conjugated with Oflx molecules to prepare antibiotic drug nanocarriers
(AgMUNH-Oflx NPs). The antibiotic drug nanocarriers at desired concentrations are
stable (non-aggregation) in a modified LB medium over time of cell culturing. We have
studied the dependence of bacterial inhibitory effects of free drug Oflx and conjugated
Oflx on the dose of Oflx and the size of nanocarriers against E. coli. Notably, we have
found that the MIC50 of free drug Oflx and conjugated Oflx significantly depend on the
dose of Oflx and the size of nanocarriers. The largest nanocarriers (92.6 ± 4.4 nm)
show the highest inhibitory effects with the lowest MIC50 (0.026 ± 0.003 µM) while the
smallest nanocarriers (2.4 ± 0.7 nm) exhibit the lowest bactericidal inhibitory with the
highest MIC50 (0.314 ± 0.010 µM) against E. coli. These results demonstrate that
inhibitory potency of the same amount of Oflx molecules could substantially elevate
when they are carried and delivered via the larger nanocarriers, suggesting that the
densely loaded Oflx molecules (multivalence) augment membrane binding affinity and
increase local drug concentrations. Interestingly, the inhibitory effects of drug
nanocarriers are dose dependent but not linearly proportional to their sizes indicating
that the tradeoff between the multivalence effects and their intracellular distribution
(pharmacodynamics) could contribute to their inhibitory effects. In addition, we have
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found that Oflx molecules can cause cellular filamentation resulting from the
unsuccessful cell division. Conjugated Oflx delivered by the largest nanocarriers
effectively induce filamentous cells confirming that the largest nanocarriers significantly
increase drug efficacy. Moreover, the MICs of free drug Oflx and conjugated Oflx in
antibiotic drug nanocarriers are size-dependent in both E. coli and P. aeruginosa (WT)
which for the same amount of Oflx molecules carried and delivered by the largest NPs
(92.6 ± 4.4 nm) are the most potent, followed by 13.0 ± 3.1 nm nanocarriers, free drug
Oflx, and 2.4 ± 0.7 nm nanocarriers. Altogether, inhibitory effects of Oflx exhibit high
dependence on the dose of Oflx and the sizes of nanocarriers. Thus, these new findings
provide the potentials to design optimal drug nanocarriers to achieve the maximum
antibiotic potency and overcome MDR in pathogenic bacterial infections.

MATERIALS AND METHODS
Reagents and Cell Line
We purchased silver nitrate (99.9%, Sigma-Aldrich), sodium citrate dehydrate
(99%, Sigma-Aldrich), sodium borohydride (98%, Sigma-Aldrich), hydrogen peroxide
(30%, Sigma-Aldrich), polyvinylpyrrolidone (PVP, Sigma-Aldrich), 2-mercaptoethanol
(99%, Sigma-Aldrich), 11-amino-1-undecanethiol hydrochloride (AUT, 99%, SigmaAldrich), ofloxacin powder (99%, Sigma-Aldrich), sodium chloride, sodium phosphate
(Sigma-Aldrich), sodium phosphate monobasic monohydrate (Sigma-Aldrich), bactotryptone and bacto yeast extract (Sigma-Aldrich). We purchased 1-Ethyl-3-[3dimethylaminopropyl]-carbodiimide

hydrochloride

(EDC,

99%,

Pierce)

and

N-

hydroxysulfosuccinimide (Sulfo-NHS, 98.5%, Pierce). We purchased silver perchlorate
monohydrate (99%, Alfa Aesar), Live/dead backlight viability assay (Life Technologies)
and Hoechst 33342 (Life Technologies). We used all reagents as received. We used
the nanopure deionized (DI) water (18 MΩ water, Barnstead) to rinse glassware and
prepare all solutions including standard LB medium (1% tryptone peptone, 0.5% yeast
extract, and 0.5% NaCl, pH = 7.2) and modified LB medium (1% tryptone peptone, 0.5%
yeast extract, and 0.1% NaCl, pH = 7.2). We purchased cell line of Escherichia coli, WT
w3110 (MsbA) from Coli Genetic Stock Center (CGSC).
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Synthesis and Characterization of Ag NPs
We had synthesized, purified and characterized three different sized Ag NPs with
diameters of (2.4 ± 0.7), (13.0 ± 3.1) and (92.6 ± 4.4) nm, as we reported previously. 2526, 42-45, 57

Briefly, we synthesized Ag NPs with diameters of 2.4 ± 0.7 nm by adding

NaBH4 (150 μL, 100 mM) into a stirring mixture (42.3 mL) of silver nitrate (0.11 mM),
sodium citrate (1.91 mM), PVP (0.052 mM), and hydrogen peroxide (25.0 mM) that
were freshly prepared using nanopure water.43

We stirred the solution at room

temperature for another 3 h and filtered the solution using 0.2 μm membrane filters. We
prepared Ag NPs with diameters of 13.0 ± 3.1 nm by rapidly adding ice-cold AgClO4
(2.5 Ml, 10 mM) into a stirring ice-cold mixture (247.5 mL) of sodium citrate (3 mM) and
NaBH4 (10 mM).27, 58 We stirred the solution at room temperature for 4 h, and filtered it
using 0.2 µm filter. We synthesized (92.6 ± 4.4) nm Ag NPs by adding sodium citrate
(10 mL, 34 mM) into a refluxing (100C) aqueous solution of 3.98 mM AgNO3 (500
mL).25, 59 We stirred the mixtures at 325 rpm for 35 min, and cooled the solution to room
temperature. We then added additional 2.5 mM sodium citrate as a stabilizer into the
solution, and filtered the solution using 0.2 µm filter.46
We purified each NP solution by thoroughly washing the NPs three times with the
DI water using centrifugation immediately after the synthesis. We characterized the NP
concentrations, the LSPR images and spectra of single NPs, and sizes of single NPs
using UV-vis spectroscopy (Hitachi U-2010), dark-field optical microscopy and
spectroscopy (DFOMS), high-resolution transmission electron microscopy (HRTEM)
(JEOL, JEM-2100F), and dynamic light scattering (DLS) (Nicomp 380ZLS particle sizing
system), respectively.46 We have fully described our DFOMS in our previous studies. 9,
12, 14, 26-28, 31, 43, 58, 60-62

In this study, the DFOMS is equipped with a dark-field optical

microscope with a dark-field condenser (oil 1.43–1.20, Nikon) and a 100× objective
(Nikon Plan fluor 100× oil, iris, SL. N.A. 0.5–1.3, W.D. 0.20 mm), a CCD camera
(Micromax, Roper Scientific) and a Multispectral Imaging System (Nuance, CRI). 43, 62
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Synthesis and Characterization of Drug Nanocarriers (AgMUNH-Oflx NPs)
We added AUT (1 mL, 100 mM, in ethanol) into the freshly prepared Ag NPs
(100 mL, 50 nM, 3.3 nM and 30 pM) of three different sized Ag NPs (2.4 ± 0.7, 13.0 ±
3.1 and 92.6 ± 4.4 nm), respectively. We stirred the mixtures for 24 h to attach AUT
onto the surface of NPs via the interaction of thiol groups with the NPs to prepare
functional AgMUNH2 NPs (Figure 2). We washed the AgMUNH2 NPs thoroughly three
times with nanopure water to remove excess AUT using centrifugation (Beckman
Optima L90k, 4C). After each washing and re-suspension step, we immediately
characterized the concentrations, optical properties and sizes of each AgMUNH 2 NP
solution using UV-vis spectroscopy, DFOMS and DLS, respectively. Note that the
AgMUNH2 NPs were suspended in DI water for the storage, and only suspended in the
respective buffer right before the experiment.
We suspended the half of purified AgMUNH2 NPs solution (50 mL) in the PBS
buffer (pH 7.0) right before control experiment. We suspended the other half of
AgMUNH2 NPs solution (50 mL) in the MES buffer (50 mM, pH 5.0) right before
conjugating them with Oflx. We conjugated the amine groups of each sized AgMUNH 2
NPs (50 mL) with the carboxyl group of Oflx via peptide bonds using a two-step method
with EDC and s-NHS as mediators (Figure 6), as described in the following. We first
dissolved Oflx in 0.5 M HCl (1 mL) and then diluted it using MES buffer (pH 5.0). We
added the EDC (100 L, 100 mM) and s-NHS (100 L, 500 mM) into the Oflx solution (3
mL, 50 mM), and stirred it at room temperature for 40 min, to form Oflx-s-NHS esters.
We added 2-mercaptoethanol to quench the excess EDC. We added the Oflx-s-NHS
esters to the AgMUNH2 NPs in the MES buffer (pH 5.0) and well mixed the solution
using a rotary shaker at room temperature for 3 h, to synthesize the AgMUNH-Oflx NPs
(nanocarriers).
We purified the drug nanocarriers (AgMUNH-Oflx NPs) by washing them with DI
water three times, and stored them at 4C for the future use. After each washing, we
immediately characterized the concentrations, optical properties and sizes of AgMUNH2
NPs using UV-vis spectroscopy, DFOMS and DLS, respectively. We measured the UV-
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vis absorbance spectra of various concentrations of nanocarriers (AgMUNH-Oflx NPs),
and plotted the peak absorbance of the nanocarriers versus their concentration to
construct a calibration curve and determine their molar absorptivity.
We measured the UV-vis absorbance spectra of various concentration of Oflx
alone (absence of NPs) in the solution, and plotted the peak absorbance at 288 nm
versus Oflx concentration to construct a calibration curve and determine its molar
absorptivity (ε288 nm = 7.8x103 M-1cm-1 and ε330 nm = 2.4x103 M-1cm-1). We subtracted UVvis absorption spectra of AgMUNH2 NPs from that of the same sized and concentration
of AgMUNH-Oflx NPs to obtain UV-vis absorption spectra of Oflx conjugated with the
AgMUNH2 NPs and used molar absorptivity of Oflx to determine its concentration. We
also determine the NP concentration based upon the peak absorbance of the plasmonic
absorption spectra of the NPs. By dividing the concentration of Oflx with concentration
of NPs in the same AgMUNH-Oflx NPs solution using UV-vis absorption spectroscopy,
we determined conjugation ratios of Oflx molecules with the NPs for each sized drug
nanocarrier.

Study of Stability of Drug Nanocarriers (AgMUNH-Oflx NPs) in Cell Culture
Medium
We characterized the stability (non-aggregation) of AgMUNH-Oflx NPs in the
commonly used standard LB medium (1% tryptone, 0.5% yeast extract and 0.5% NaCl
in DI water, pH = 7.2) and the modified medium (1% tryptone, 0.5% yeast extract and
0.1% NaCl in DI water, pH = 7.2) over 24 h using UV-vis absorption spectroscopy. We
found that the nanocarriers with the diameters of Ag NPs of (2.4 ± 0.7, 13.0 ± 3.1 and
92.6 ± 4.4 nm) at a desired concentration (6.0 nM, 0.8 nM and 7 pM) are stable (nonaggregated) in the modified medium over 24 h, but they are unstable (aggregated) in
the standard medium, respectively.
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Cell Line, Cell Culture Medium, Cell Culture and Characterization
Gram-negative E. coli (MsbA) strain was cultured in the standard and the
modified LB medium and the cell growth was studied. We first pre-cultured the cells in a
standard LB medium in an incubated floor shaker (Thermo Scientific, MaxQ5000) (160
rpm, 37 °C) for 12 h. We then cultured the cells in either the standard LB medium or the
modified LB mediums in the incubated floor shaker (160 rpm, 37 °C) for another 8 h. We
followed the cell growth in each medium over time and characterized the cell growth
curves by measuring OD600

nm

of cell suspension in every 30 min for over 8 h.

Furthermore, we studied viability of the cultured cells at the end of the experiment at a
single cell resolution using LIVE/DEAD BacLight viability and counting assay.63 We
imaged cells in the micro-chamber using dark-field optical microscopy and epifluorescence microscopy and counted the green fluorescence cells (peak wavelength of
fluorescence spectra of SYTO9, λmax = 520 nm) and the red fluorescence cells (peak
wavelength of fluorescence spectra of propidium iodide, λmax = 610 nm) as live and
dead cells, respectively.
By the end of the cell culture, we studied cell efflux function using time course of
fluorescence dye accumulation in intact cells overtime. We harvested the cells using
centrifugation (Beckman Model J2-21 Centrifuge, JA-14 rotor, at 7500 rpm, 23 °C, 10
min), washed the cells with the PBS buffer (0.5 mM phosphate buffer, 1.5 mM NaCl, pH
7.2) for three times, and finally re-suspended the cells in the buffer. The final
concentration of the cells was adjusted to OD600 nm = 0.1.9, 28, 31, 60, 64 Time-dependent
fluorescence intensity of Hoechst 33342 (0.5 µM) incubated with cells with a presence
and an absence of orthovanadate (25 µM) was measured at a 10-s data acquisition
interval in real time using a fluorescence spectrometer (Cary Eclipse). The excitation
and emission wavelengths were 354 and 478 nm, respectively.

Study of Inhibitory Effects of Drug Nanocarriers (AgMUNH-Oflx NPs)
We cultured the cells (104 pre-cultured cells) in the modified LB medium (2.5 mL)
containing a dilution series of ofloxacin alone and a conjugated ofloxacin from given
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sized antibiotics drug nanocarriers and incubated the cells in an incubated floor shaker
(Thermo Scientific, MaxQ5000) with vigorous shaking (200 rpm, 37ºC) over 18 h.
The dilution series consist of 0, 0.045, 0.09, 0.18, 0.38 and 0.68 µM of free drug
Oflx or conjugated Oflx from the nanocarriers, which is corresponded to the
concentrations of nanocarriers (NP concentrations): (i) 5.21x10 -2, 0.104, 0.209, 0.440,
and 0.788 nM for NPs with a diameter of 2.4 ± 0.7 nm with the ratio of 8.6x102 Oflx
molecules per NP; (ii) 4.77x10-3, 9.54x10-3 , 1.91x10-2, 4.03x10-2 and 7.21x10-2 nM for
NPs with a diameter of 13.0 ± 3.1 nm with the ratio of 9.4x103 Oflx molecules per NP;
(iii) 6.89x10-2, 0.138, 0.276, 0.582 and 1.04 pM for NPs with a diameter of 92.6 ± 4.4 nm
with the ratio of 6.5x105 Oflx molecules per NP. In addition, control experiments
included the modified LB medium alone (No cells) and the cells, which were cultured at
the same time and under the same conditions as samples, incubated with the modified
LB medium containing 0.788 nM, 7.21x10-2 nM and 1.04 pM AgMUNH2 NPs (in the
absence of Oflx) with a diameter of Ag NPs of 2.4 ± 0.7, 13.0 ± 3.1 and 92.6 ± 4.4 nm,
respectively.
The cell solutions were sampled every 6 h and quantitatively determined the
bacterial cell concentration by measuring OD600 nm in a 96-well plate using a plate reader
(BioTek SynergyHT) equipped with an UV-vis absorption spectral detector. We plotted
OD600

nm

of the cell suspension over time to determine the time (18 h) for the cells

reached their confluence. Thus, we used the OD600 nm of each cell suspension at 18 h to
determine the inhibitory effects of the free drug Oflx and conjugated Oflx as described in
the following.
The OD600 nm of each cell suspension was normalized with the maximum OD600 nm
(the cells cultured in the medium alone, blank control) among the dilution series of the
cell suspensions for each type of samples (e.g., free Oflx, each sized nanocarriers),
respectively. We then plotted the normalized OD600 nm of the cell suspension versus the
concentration of free drug Oflx (Oflx alone) or concentration of Oflx conjugated with a
given sized drug nanocarrier to determine the MIC50 of Oflx.

We repeated each

experiment three times and plotted the average of three experimental measurements for
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each sample with a standard deviation of the normalized OD600

nm

of each cell

suspension (points in Figure 13). We fitted the points using the exponential decay (y =
a*e-bx, inhibitory effects upon the exponential cell growth) to determine the parameters
(a, b) of the equation with the highest possible regression. The equation was then used
to determine the MIC50 (the concentration of Oflx at which the cell growth was inhibited
to the half of the cell growth of the blank control experiment), as described in Figure 13
caption. The points in Figure 13 are experimental data and a solid line is generated by
fitting the experimental data with an equation (y = a*e-bx) as followings: (D) y = 1.12 e5.57x,

R2 = 0.944; (D) y = 1.12 e-2.56x, R2 = 0.928; (F) y = 1.08 e-9.58x, R2 = 0.941; (G) y =

1.01e-26.7x, R2 = 0.988. Concentrations of Oflx (MIC, IC50) for free Oflx and Oflx
conjugated with a given sized nanocarrier were determined using the exponential fitting
equation at the half of the maximum normalized OD 600 nm for each curve, respectively.
The “a” and “b” in the equation for each sample were determined based upon the best
fitting (the highest regression with the lowest error). As a control experiment, we also
plotted the normalized OD600 nm of the cell suspension at 18 h versus the concentration
of AgMUNH2 NPs (absence of Oflx) that is the same as the highest concentration of the
given nanocarrier for each cell strain.
In addition to measuring OD

600 nm,

we sampled the cell solutions every 6 h and

prepare cells in a micro chamber for imaging using DF microscope to observe cell
morphologies. We took five representative locations of each sample.

Data Analysis and Statistics
We characterized sizes and shapes of Ag NPs using TEM, and LSPR spectra of
single Ag, AgMUNH2, and AgMUNH-Oflx NPs using DFOMS.46 We imaged at least 100
NPs for each size and type of NPs per measurement and repeated each experiment
three times for each individual size. Therefore, a minimal of 300 NPs was characterized
using TEM and DFOMS.46 We ran experiments including the study of stability of NPs in
the medium, cell growth curves, and determination of drug inhibitory effects three times
on each concentration and for each size of antibiotic drug nanocarriers. We used
average of three measurements with standard deviations for each study.
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CHAPTER III

SINGLE ANTIBIOTIC NANOCARRIER OPTICAL PROBES FOR STUDY OF
SUBSTRATE-DEPENDENT EFFLUX FUNCTION OF MULTIDRUG ABC MEMBRANE
TRANSPORTERS IN SINGLE LIVE ESCHERICHIA COLI CELLS

INTRODUCTION
The ATP-binding cassette (ABC) membrane transporters (efflux pumps) are
highly conserved proteins existing in a variety of prokaryotes and eukaryotes.1-3 They
use the energy of ATP binding and hydrolysis to transport a large number of structurally
and functionally unrelated substrates across biological membranes.1-3 Multidrug ABC
transporters can extrude antibiotics out of bacterial cells and chemotherapeutic agents
from cancer cells (e.g., P-glycoproteins, Pgp) resulting in multidrug resistance (MDR)
and the failure of numerous treatments of infections and cancers. 2-4

All ABC

transporters share a similar modular topology including two transmembrane domain
(TMD) and two nucleotide binding domain (NBD).1,

3, 7-8

The TMDs, which contain the

large diversity of selective substrate binding sites, form the transmembrane channel for
substrates to cross the membrane whereas the NBDs, which are a hallmark of this
transporter and more highly conserved, couple conformational changes induced by ATP
hydrolysis leading to the extrusion of the substrates out of the cells against
concentration gradients across the cellular membrane.1, 3, 7-8 This process is called as
efflux function.
MsbA, an essential homodimeric (2 x 65 kDa) ABC membrane transporters in
Gram-negative bacteria (e.g., Escherichia coli), shares structural and functional
similarities and is the most closely to Pgp which is a multidrug ABC membrane
transporter found in cancer cells.1,

5

Its primary function is translocation of lipid A and

lipopolysaccharide (LPS) from the cytoplasmic leaflet (inward-facing) to the periplasmic
leaflet (outward-facing) of bacterial inner membrane using ATP hydrolysis as an energy
source.1-2,

5, 8, 40

Functional studied have also shown that MsbA can recognize and

extrude a wide variety of drug spectrums and confers resistance to certain antibiotics. 1,

46

10, 65

MsbA is an ATPase which is stimulated by substrates, such as lipid A, LPS and

multiple drugs, and it is inhibited by orthovanadate (Na3VO4).40 Adenosine diphosphate
(ADP) is stably trapped in the active site, with orthovanadate occupying the position of
the gamma phosphate. The orthovanadate appears to interact with five oxygen
mimicking the gamma phosphate during the transition state for ATP hydrolysis.66-67
Notably, ATPases are involved in various cellular processes, such as intracellular
transports and DNA replication making them attractive targets for drug discovery.
Currently, a number of ATPase inhibitors are in clinical trials. For example, Tariquidar
(XR9576)

is

a

Pgp

inhibitor

that

is

administrated

in

a

combination

with

chemotherapeutic agents such as doxorubicin, docetaxel or vinorelbine.68-69
Despite the increasing number of available crystal and cryo-EM structures of
ABC transporters, many questions related to the molecular basis of the transport
mechanisms involving in substrate recognition, translocation and coupling to ATP
hydrolysis are still elusive.

1-2, 7-8

One of the most interesting questions is how ABC

transporters extrude numerous structurally unrelated hydrophobic and amphipathic
compounds out of the cells. The identification of the drug-binding sites in Pgp found at
the interface between the TMDs, suggests a large and flexible drug-binding cavity that
can accommodate multiple substrates via interactions with aromatic and hydrophobic
residues.3,

70

We hypothesize that individual efflux pumps might process a substrate

sensing machinery which can specifically recognize a given noxious pump substrate
(e.g., antibiotics and chemotherapeutic agents) and extrude it out of the cells,
underscoring the importance of characterization of efflux function in single live cells in
real time. Although X-ray crystallography and cryo-EM are the primary techniques to
depict the structures of membrane transporters at the atomic resolution, 2,

71-73

unfortunately they cannot provide real-time dynamic insights into how the efflux pumps
selectively recognize and interact with structurally unrelated substrates and then
translocate membrane transporters to extrude the substrates out of the cells. 2, 71-73
Conventional methods for the study of transport efflux kinetics in bulk bacterial
cells include the use of radioisotopes (14C and 3H) or fluorophores (ethidium bromide
and Hoechst dye) as probes to measure accumulation of substrates in the cells. 9-12

47

Study of the accumulation kinetics of bulk could have masked rare interesting events as
individual cells act differently and their efflux kinetics are unsynchronized. 13-14
Therefore, it is important to probe efflux kinetics of individual membrane transporters in
single live cells in real time.13-14 Moreover, radioisotopes or fluorophores are unable to
measure sizes of substrates and membrane transporters as they lack of distinctive sizedependent physicochemical properties. Thus, these conventional probes are not
suitable to serve as various size-dependent pump substrates for the study of efflux
function of single membrane transporter in single live cells in real time.
Noble metal nanoparticles (e.g., silver nanoparticles, Ag NPs) possess distinctive
size-dependent photostable plasmonic optical properties which highly depend on their
sizes, shapes, dielectric constants and surrounding environments. 23-24, 74 These features
enable us to image and determine the sizes of single NPs at the nanometer (nm)
resolution in real time using dark-field optical microscopy and spectroscopy (DFOMS).9,
13-14, 29, 43, 58-59, 61-62, 75-77

Furthermore, we have demonstrated that we can use size-

dependent localized surface plasmon resonance (LSPR) spectra and size-dependent
scattering intensity of single Ag NPs as photostable optical probes which mimic various
sizes of antibiotics to study the size-dependent efflux kinetics of multidrug membrane
transporters in single live cells in real time.9, 13-14,

29

Moreover, we have functionalized

Ag NPs with biocompatible peptides and studied the dependence of efflux function of
single BmrA membrane transporters in Bacillus subtilis (Gram-positive bacteria) upon
charged substrates.13
We synthesized, purified and characterized antibiotic drug nanocarriers (2.4 ± 0.7
nm

AgMUNH-Oflx NPs) by functionalizing nanocarriers (AgMUNH2 NPs) with

antibiotics (Ofloxacin, Oflx) to have 8.6 x 102 Oflx molecules per NP, as described
previously.46 We found that the AgMUNH-Oflx NPs exhibited inhibitory effects whereas
the AgMUNH2 NPs did not show significant inhibitory effects on the cell growth.46 In this
study, due to distinctive LSPR spectra of Ag NPs (color), we used the AgMUNH-Oflx
NPs (antibiotic drug nanocarriers) and the AgMUNH2 NPs (control nanocarriers without
drug) as powerful imaging probes aiming to study substrate-dependent efflux function of
single MsbA membrane transporters in single live E. coli cells to observe whether
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curtain types of substrates play a key role in the selective extrusion of efflux pumps and
to determine the pore size of the transporters. This study offers a possibility to address
how the structurally similar membrane transporters could selectively extrude a plethora
of structurally unrelated substrates. To our knowledge, study of efflux function of MsbA
transporters in single live E. coli cells using such small sized drug nanocarriers has not
yet been reported. It remains elusive whether the MsbA possesses substrate-dependent
efflux function. Better understanding of efflux mechanisms of multidrug membrane
transporters could provide new insights into rational designs of drugs or drug carriers to
improve drug efficacy and avoid MDR.

RESULTS AND DISCUSSION
Real-time Probing of Efflux Kinetics of Membrane Transporters Using Single
Antibiotic Drug Nanocarriers
We suspended the cells in a PBS buffer (0.5 mM phosphate buffer saline with 1.5
mM NaCl, pH = 7.0) rather than in cell culture medium. The cells grow and divide in the
cell culture medium leading to the change of cell concentration and cellular growth
stages over time. This makes results incomparable with other experiments.9,

13-14, 29-30

Consequently, we incubated bacterial cells in the PBS buffer at a given concentration
and a certain growth stage with given concentrations of pump substrates (e.g.
fluorescence dyes or Ag NPs) to determine the dependence of substrate accumulations
and efflux kinetics of membrane transporters in a given cell strain.9,

13-14, 29-30

We

incubated the cells (OD600 nm = 0.7) with 2.4 ± 0.7 nm AgMUNH-Oflx NPs (antibiotic drug
nanocarriers) or the AgMUNH2 NPs (control nanocarriers without drug) and then tracked
single nanocarriers in and out of single live cells in real time using DFOMS.
Representative dark-field optical images of the single live E. coli cells (MsbA-WT)
(Figure 15, 16: A) with single intracellular and extracellular nanocarriers as boxed show
cross-sections of single rod-shaped bacterial cells with 2 µm in length and 0.5 µm in
width. As described previously,

9, 12-14, 29-30, 75

the cell membranes above and below the

focal plane (190 nm depth of field) become invisible under dark-field illumination
because they are out of the focal plane of the dark-field microscope, allowing us to
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image thin-layer cross sections of single bacterial cells and track single nanocarriers on
the thin-layer membrane section.
The illumination of dark-field microscopy requires to pass into the cellular
membrane to radiate the intracellular NPs and scattering of intracellular NPs must be
transmitted through the membrane to reach the detector. The cellular membrane absorb
photon causing a dimmer intensity of intracellular NPs (Figure 15B, 16B: a). Moreover,
as intracellular NPs are located inside the cell membrane, they are out of the focus
plane and appear blurry. On the other hand, scattering of extracellular NPs is a
combination of the scattering intensity of NPs and the cell membrane leading to a higher
scattering intensity and brighter images (Figure 15B, 16B: b). We have shown that
these distinctive properties and scattering intensity of NPs are practical to distinguish
intracellular NPs and extracellular NPs in the study of efflux function of multidrug
membrane transporters in real time.9,

13-14, 28-30

In this study, we use this validated

approach to determine intracellular and extracellular NPs. Intracellular AgMUNH-Oflx
NPs (Figure 15B: a) and AgMUNH2 NPs (Figure 16B: a) are dimmer, blurry and exhibit
a lower scattering intensity than extracellular AgMUNH-Oflx NPs (Figure 15B: b) and
AgMUNH2 NPs (Figure 16B: b). The representative LSPR spectra of single AgMUNHOflx NPs (i – iii) in Figure 15C show the peak wavelength and full-width-at-halfmaximum (FWHM) at 524 (85), 535 (101), and 550 (123) nm, respectively. In addition,
the representative LSPR spectra of single AgMUNH2 NPs (i – iii) in Figure 16C show the
peak wavelength and FWHM at 531 (109), 551 (109), and 538 (104) nm, respectively.
These distinctive LSPR spectra of single NPs (Figure 15, 16: C) enable us to effectively
identify NPs from other cellular debris and other substances which lack of plasmonic
properties, therefore they appear white under dark-field illumination.9, 13-14, 29-30 Notably,
individual Ag NPs process unique LSPR spectra depending on their sizes, shapes and
surrounding environment enable us to use single Ag NPs as individual imaging
probes.23-24, 43
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Figure 15. Imaging of single intracellular and extracellular 2.4 ± 0.7 nm AgMUNHOflx NPs in single living bacterial cells using DFOMS.
(A) The representative optical image of bacterial cells incubated with 1.4 nM AgMUNHOflx NPs showing intracellular and extracellular NPs as squared. (B) Zoom in optical
color (i and iii) and CCD (ii and iv) images of single cells show (a) intracellular and (b)
extracellular NPs which are pseudo colored in color images. The scale bar in A and B
are 10 and 2 µm, respectively. (C) LSPR spectra of representative single 2.4 ± 0.7 nm
AgMUNH-Oflx NPs (i-iii) show peak wavelengths and full width at half maximum
(FWHM) at 524 (85), 535 (101), and 550 (123) nm, respectively.
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Figure 16. Imaging of single intracellular and extracellular 2.4 ± 0.7 nm AgMUNH2
NPs in single living E. coli cells using DFOMS.
(A) The representative optical image of bacterial cells incubated with 1.4 nM AgMUNH 2
NPs showing intracellular and extracellular NPs as squared. (B) Zoom optical color (i
and iii) and CCD (ii and iv) images of single cells show (a) intracellular and (b)
extracellular NPs which are pseudo colored in color images. The scale bar in A and B
are 10 and 2 µm, respectively. (C) LSPR spectra of representative single 2.4 ± 0.7 nm
AgMUNH2 NPs (i-iii) show peak wavelengths and full width at half maximum (FWHM) at
531 (109), 551 (109), and 538 (104) nm, respectively.
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We found that the peak wavelength of the AgMUNH2 NPs are at the longer
wavelength than those of the AgMUNH-Oflx NPs. This might be due to size distribution
of the NPs (range 1- 5 nm)46 where the sizes of these individual AgMUNH2 NPs could
be larger than these individual AgMUNH-Oflx NPs. Moreover, we determined the sizes
of NPs and tracked the stability (non-aggregation) and transports of single NPs inside
and outside the membrane of single live cells in situ in real time. For example, if
individual NPs aggregated and became the larger NPs, we would have observed the
huge red-shifted of LSPR spectra and color change of the NPs. We did not observe
such a phenomenon during each experiment (2 h) indicating that the NPs are stable
(non-aggregated) in the PBS buffer and inside the cells over time. In short, we used
plasmonic features of the Ag NP-based antibiotic drug nanocarriers (AgMUNH-Oflx
NPs) and the control nanocarriers (AgMUNH2 NPs) to characterize the number of
nanocarriers and monitor them in situ in real time as they transported in and out the
cellular membrane over time using the same approach described previously. 9, 13-14, 29-30
Single Ag NPs are photostable, unlike fluorescence probes, which enable us to probe
efflux function of multidrug membrane transporters using antibiotic drug nanocarriers
over time.9, 13-14, 29-30, 43

Insights into Pump Substrates and Effects of Pump Inhibitor on Accumulation
Rates of Antibiotic Drug Nanocarriers in Single Live Cells
Differently from eukaryotes, prokaryotes (bacterial cells, such as E. coli) do not
have endocytosis pinocytosis and exocytosis. Therefore, these cellular processes are
not responsible for the transport of NPs in and out the live bacterial cells. We studied
the accumulation rates of the antibiotic drug nanocarriers (AgMUNH-Oflx NPs) and the
control nanocarriers (AgMUNH2 NPs) in MsbA (WT) living cells to determine whether
the NPs are substrates of MsbA. The results in Figure 17A, B: b and Table 3 show that
the cells accumulate the intracellular NPs over time. The accumulation rates of
intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs during their incubation with 1.4 nM
NPs over 41.5 min are 1.03 and 2.16 intracellular NPs/min, respectively (Table 3). We
further study the effects of a pump (ATPase) inhibitor, orthovanadate (Na3VO4) to
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determine whether MsbA membrane transporters are specifically responsible for the
efflux of the nanocarriers. Note that MsbA is an ATPase which is stimulated by
substrates such as lipid A, lipopolysaccharide (LPS) and multiple drugs, and it is
inhibited by orthovanadate.40 The results in Figure 17A, B: b and Table 3 show that the
cells accumulate the intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs much more
rapidly in the presence of orthovanadate. The accumulation rates of intracellular
AgMUNH-Oflx NPs and AgMUNH2 NPs during their incubation with 1.4 nM NPs over
41.5 min in the presence of orthovanadate are 3.61 and 4.52 intracellular NPs/min,
respectively (Table 3). We found that the numbers of intracellular AgMUNH-Oflx NPs
and AgMUNH2 NPs significantly increased when the cells were incubated with
orthovanadate (p < 0.0005). These findings suggest the high dependence of
accumulation rates of intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs upon the
pump function of MsbA in the presence of the inhibitor. Taken together, the results in
Figure 17 and Table 3 indicate that MsbA (WT) is indeed responsible for the extrusion
of the intracellular NPs out of the cells and the pump function is hindered by the inhibitor
leading to an increase of the accumulation of intracellular NPs in the absence of the
inhibitor.
The size of antibiotic drug nanocarriers are order of magnitude larger than those
of conventional antibiotics. It seems almost impossible that these nanocarriers can
permeate into the cells and be extruded out by the efflux pumps. To determine whether
the antibiotic drug nanocarriers cause any possible steric effects to efflux pumps and
they are suitable substrates for probing the efflux function, we used a fluorescence dye
(Hoechst 33342) to study the dependence of accumulation kinetics probing the efflux
function of MsbA (WT) in the presence and its absence of orthovanadate. The Hoechst
dye is a well-known substrate of MsbA (ABC) membrane transporters and has been
commonly used in studies of efflux function.10-11 Fluorescence intensity of the dye is
weak in aqueous solution but it dramatically increases when the dye internalizes into the
cells and intercalates with DNA.47 The cells incubated with orthovanadate (Figure 17C:
a) accumulated more amount of intracellular dye molecules with the higher rate of
accumulation (slopes of the curves) than those were not incubated with orthovanadate
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Figure 17. Study of effects of a pump (ATPase) inhibitor, orthovanadate on the
accumulations of single 2.4 ± 0.7 nm AgMUNH-Oflx NPs, AgMUNH2 NPs, and
fluorescence dye (Hoechst 33342) molecules.
(A) Plots of number of intracellular AgMUNH-Oflx NPs (A) and AgMUNH2 NPs (B) and
plots of the fluorescence intensity of Hoechst 33342 dye (C) over time in the presence
(a, solid) and absence (b, empty) of the inhibitor (25 µM). In (A) and (B), the points
represent the experimental measurements and the lines are added to guide the trend.
At each time point (25 min), 900 cells were analyzed. In (A) and (B), the p values of
data in (a) and (b) are less than 0.0005 (<0.0005), indicating statistically significant
difference of intracellular NPs in the presence (a) and absence (b) of orthovanadate,
and the dependence of accumulation kinetics of the NPs on the pump inhibitor.
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Table 3. Summary of Accumulation Rates and Numbers of Intracellular Single 2.4
± 0.7 nm NPs in Single Living E. coli Cells

Types of NPs
AgMUNH-Oflx

AgMUNH2

C Ag NPs

Inhibitor a

Accumulation rate

Numbers of

(nM)

(µM)

(NPs min-1) b

intracellular NPs c

0.7

0

0.59

25

1.4

0

1.03

43

1.4

25

3.61

150

0.7

0

1.38

57

1.4

0

2.16

90

1.4

25

4.52

188

a

Orthovanadate;

b

Accumulation rates (slopes of the plots) at the 41.5 min incubation;

c

Numbers of intracellular NPs accumulated in 900 live cells at the 41.5 min incubation.
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(Figure 17C: b). The results in Figure 17C are similar to those observed using the
AgMUNH-Oflx NPs (Figure 17A) and the AgMUNH2 NPs (Figure 17B) indicating that the
AgMUNH-Oflx NPs and the AgMUNH2 NPs are substrates of MsbA membrane
transporter and well suited as small fluorescence molecules for the study of efflux
kinetics of single MsbA membrane transporter in single live cells. Unlike fluorescence
probes, LSPR of plasmonic single NPs provide information regarding the sizes of pump
substrates and the pore sizes of membrane transporters which enable us to determine
the size-dependent efflux kinetics of multidrug membrane transporters. Taken together,
we demonstrate that the efflux pumps can extrude the small sized drug nanocarriers out
of the cells and we can track them to study efflux function of MsbA in single cells in real
time.

Study of Concentration Dependence on Accumulation Rates of Antibiotic Drug
Nanocarriers in Single Living Cells
We further studied how the antibiotic drug nanocarriers (AgMUNH-Oflx NPs) and
the control nanocarriers (AgMUNH2 NPs) enter the cells and whether they passively
diffuse into the cells as same as those conventional pump substrates, such as
antibiotics. Thus, we determined the accumulation rates of single AgMUNH-Oflx NPs
and AgMUNH2 NPs upon their concentrations (0.7 and 1.4 nM). The results in Figure 18
show that the number of intracellular of both AgMUNH-Oflx NPs (Figure 18A) and
AgMUNH2 NPs (Figure 18B) significantly depends on the NP concentration (AgMUNHOflx NPs, p < 0.0005 and AgMUNH2 NPs, p < 0.0005), and the number of intracellular
NPs increases as the NP concentration increases at any given incubation time. As the
NP concentration increases from 0.7 to 1.4 nM, the number of intracellular AgMUNHOflx NPs accumulated in single live cells increases from 25 to 43 within 41.5 min at the
rates of 0.59 and 1.03 NPs/min, respectively, and similarly the number of intracellular
AgMUNH2 NPs accumulated in single live cells increases from 57 to 90 within 41.5 min
at the rates of 1.38 and 2.16 NPs/min, respectively.
Likewise, we found the concentration dependence of the accumulation of
fluorescence dye (Hoechst 33342) where the dye at a higher concentration (Figure 18C:
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a) passively entered the cells more rapidly and accumulated inside the cells more than
that at the lower concentration (Figure 18C: b). These findings suggest that both
AgMUNH-Oflx NPs and AgMUNH2 NPs most likely passively diffuse into the cells and
be extruded out of the cells by MsbA transporters similarly to conventional antibiotics.
The diffusion rates of AgMUNH-Oflx NPs and AgMUNH2 NPs show high dependence on
the concentration gradients of the NPs across the cellular membrane of single cells and
the diffusion rates increase as the NP concentration gradients increase and vice versa.
In contrast, the efflux of substrates (e.g., AgMUNH-Oflx NPs and AgMUNH2 NPs) out of
the cells against concentration gradients is an active transport process which requires
ATP energy and depends on substrate selectivity. Thus, the efflux rates of the
AgMUNH-Oflx NPs and AgMUNH2 NPs are not proportional to the NP concentration
and interestingly the accumulation of intracellular AgMUNH2 NPs rises more rapidly than
those of the AgMUNH-Oflx NPs as NP concentration increases.
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Figure 18. Study of the concentration dependent accumulations of 2.4 ± 0.7 nm
AgMUNH-Oflx NPs, AgMUNH2 NPs, and fluorescence dye (Hoechst 33342)
molecules in living E. coli cells.
(A) Plots of number of intracellular AgMUNH-Oflx NPs in E. coli incubated with 1.4 nM
(a) and 0.7 nM (b) of AgMUNH-Oflx NPs versus time. (B) Plots of number of intracellular
AgMUNH2 NPs in MsbA incubated with 1.4 nM (a) and 0.7 nM (b) of AgMUNH 2 NPs
versus time. (C) Plots of fluorescence intensity of Hoechst 33342 dye at 1 µM (a) and
0.5 µM (b) versus time. In (A) and (B), the points represent the experimental
measurements and the lines are added for trend projection. Note that 900 cells were
analyzed at each point (every 25 min). The p values of data in (a) and (b) are less than
0.0005 (<0.0005), indicating statistically significant difference of intracellular NPs in the
cell incubated with (a) 1.4 nM and (b) 0.7 nM at 95% confidential level, and
concentration dependent efflux functions of MsbA.

59

Study of Substrate-Dependent Accumulation Rates of Single Drug Nanocarriers
in Single Live Cells
It is worth noting that the accumulation of intracellular AgMUNH-Oflx NPs and
AgMUNH2 NPs in single live cells in the presence and its absence of orthovanadate
strongly suggest the dependence on types of substrates. The number of intracellular
AgMUNH2 NPs are significantly higher than the number of intracellular AgMUNH-Oflx
NPs in both 0.7 nM (p < 0.0005) and 1.4 nM (p < 0.0005) concentrations (Figure 18).
We observed twice higher accumulation rates of AgMUNH2 NPs in single live cells than
those of AgMUNH-Oflx NPs over 41.5 min. Interestingly, the number of intracellular
AgMUNH2 NPs is only significantly higher than those of AgMUNH-Oflx NPs in single live
cells in the absence of orthovanadate (p < 0.0005) but it is not in its presence of
orthovanadate. These findings suggest that MsbA extrudes the AgMUNH-Oflx NPs
more effectively than the AgMUNH2 NPs because the intracellular AgMUNH-Oflx NPs
increase much greater than the AgMUNH2 NPs when the inhibitor disrupts efflux
function. As the AgMUNH-Oflx NPs differ from the AgMUNH2 NPs with regards to their
multiple conjugated Oflx molecules which exhibit inhibitory effects, the plausible
explanation why the cells extrude the AgMUNH-Oflx NPs more effectively is that they
could selectively extrude noxious molecules as cellular defense mechanisms. This
could lead to further studies to address how multidrug membrane transporters can
selectively extrude a large number of chemically and functionally unrelated substances
out of the cells and how MDR occurs.
Quantitative accumulation rates of intracellular AgMUNH-Oflx NPs and
AgMUNH2 NPs in single living cells (Figure 17 and 18) are summarized in Table 3. We
demonstrate that both the AgMUNH-Oflx NPs and AgMUNH2 NPs are substrates of
MsbA membrane transporters and they are suitable optical probes to study efflux
function of MsbA membrane transporters in single live cells. These results indicate the
dependence of accumulation kinetics of single NPs in single live cells on types of
substrates, the pump inhibitor and the concentration of NPs.
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Characterization of the Viability of Single Cells
We have reported that antibiotic drug nanocarriers with a diameter of 2.4 ± 0.7
nm inhibited bacterial growth in a dose-dependent manner.46 Therefore, we
characterized the viability of the cells MsbA (WT) to ensure that the doses of the
antibiotic drug nanocarriers (AgMUNH-Oflx NPs), the control nanocarriers (AgMUNH2
NPs) and the pump inhibitor that we used to probe efflux function of E. coli did not
cause cell death and interfere with their pump function. We characterized viability of the
cells incubated with the antibiotic drug nanocarriers (AgMUNH-Oflx NPs) or the control
nanocarriers (AgMUNH2 NPs) throughout the duration of the experiment over 2 h using
LIVE/DEAD BacLight assay. The green SYTO9 fluorescence dye (λmax = 520 nm) stains
cellular nucleic acids which identify the live cells while the red PI fluorescence dye (λ max
= 610 nm) penetrates into only the cells with disintegrated membrane which detect the
dead cells.63
Representative optical images of the cells incubated with AgMUNH-Oflx NPs (1.4
nM) in the presence (Figure 19A: a) and absence (Figure 19B: a) of orthovanadate (25
µM) over 2 h show the cells with and without NPs. Their fluorescence images illustrate
the green fluorescence but not the red fluorescence indicating that the cells are viable
(Figure 19A, B: b). We determined percentage of live and dead cells by dividing the
number of viable cells by the total number of cells. We found that 99 % of the cells
incubated with 1.4 nM AgMUNH-Oflx NPs in the presence and absence of
orthovanadate (25 µM) (Figure 19C) were viable. Similarly, representative optical
images of the cells incubated with AgMUNH2 NPs (1.4 nM) in the presence (Figure 20A:
a) and absence (Figure 20B: a) of orthovanadate (25 µM) over 2 h show the cells with
and without NPs. The cells emitted green fluorescence but not red fluorescence
suggesting that they were viable (Figure 20A, B: b). The results show that 99 % of the
cells are alive (Figure 20C). As the cells with the NPs and orthovanadate are all alive,
the accumulation rates of the NPs in single live cells are associated with NP passive
diffusion and efflux function of the membrane transporters but not the compromised
membrane integrity due to the cell death. The findings further demonstrate that the
doses (0.7 and 1.4 nM) of the AgMUNH-Oflx NPs are suitable to use in study MDR and
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Figure 19. Characterization of viability of single bacterial cells incubated with 2.4
± 0.7 nm AgMUNH-Oflx NPs using LIVE/DEAD BacLight viability and counting
assay.
In (A) and (B), representative dark field optical image (a) and fluorescence image (b) of
single bacterial cells (MsbA), incubated with 1.4 nM AgMUNH-Oflx in the presence (A)
and absence (B) of the inhibitor (25 µM) over the duration of each experiment for 2 h,
show that the cells with intracellular NPs (as squared) or without NPs emit the green
fluorescence (λ

max

= 520 nm) of SYTO9, indicating that cells are viable. (C) Plots of

percentage of viable cells (a) and dead cells (b) of MsbA incubated with 1.4 nM
AgMUNH-Oflx with and without the inhibitor, indicate that 99 % of the cells are alive.
Minimum 300 cells were assayed and analyzed. The scale bar is 5 µm.
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Figure 20. Characterization of viability of single bacterial cells incubated with 2.4
± 0.7 nm AgMUNH2 NPs using LIVE/DEAD BacLight viability and counting assay.
In (A) and (B), representative dark field optical image (a) and fluorescence image (b) of
single bacterial cells (MsbA), incubated with 1.4 nM AgMUNH2 in the presence (A) and
absence (B) of the inhibitor (25 µM) over the duration of each experiment for 2 h, show
that the cells with intracellular NPs (as squared) or without NPs emit the green
fluorescence (λ

max

= 520 nm) of SYTO9, indicating that cells are viable. (C) Plots of

percentage of viable cells (a) and dead cells (b) of MsbA incubated with 1.4 nM
AgMUNH2 with and without the inhibitor, indicate that 99 % of the cells are alive.
Minimum 300 cells were assayed and analyzed. The scale bar is 5 µm.
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efflux function of multidrug membrane transporter of antibiotic drug nanocarriers in
bacteria.

SUMMARY
We synthesized, purified and characterized Ag NP-based antibiotic drug
nanocarriers (AgMUNH-Oflx NPs) with a diameter of 2.4 ± 0.7 nm containing 8.6 x 102
Oflx molecules per NP.46 The NPs up to 1.4 nM are stable (non-aggregated) in the PBS
buffer and biocompatible with the cells (MsbA WT) over the experimental period (2 h).
Due to distinctive features of Ag NPs, we are able to image and track such small single
antibiotic drug nanocarriers as they transport in and out live single bacterial cells and
use LSPR spectra of single AgMUNH-Oflx NPs and AgMUNH2 NPs (absence of Oflx,
control nanocarriers) study efflux function of MsbA membrane transporters in single live
cells. We found that the accumulation rates of both AgMUNH-Oflx NPs and AgMUNH2
NPs highly depend on the concentration of NPs and a pump inhibitor (orthovanadate),
similar to those observed using a well-known substrate (Hoechst dye 33342) of MsbA
membrane transporters, suggesting that the AgMUNH-Oflx NPs and AgMUNH2 NPs are
substrates of MsbA membrane transporters and they passively diffuse into the cells.
Interestingly, we observed twice higher accumulation rates of AgMUNH 2 NPs in single
live cells than those of AgMUNH-Oflx NPs, suggesting substrate-dependent efflux
kinetics of MsbA (WT) membrane transporters in single live cells and their potential
capabilities to detect, recognize and extrude toxic substrates (e.g., antibiotics or
anticancer drugs) efficiently. These findings agree with our previous study that the
AgMUNH-Oflx NPs exhibit inhibitory effects while the AgMUNH2 NPs are biocompatible
with the cells.46 These results provide a new evidence that multidrug membrane
transporter might have a sensing machinery to detect and recognize toxic substrates,
which lead to further studies to address molecular basis of efflux mechanisms about
how multidrug membrane transporters can selectively extrude a large number of
chemically and functionally unrelated substances out of the cells.
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MATERIALS AND METHODS
Reagents and Cell Line
We purchased sodium chloride, sodium phosphate (Sigma-Aldrich), sodium
phosphate monobasic monohydrate (Sigma-Aldrich), bacto-tryptone and yeast extract
(Sigma-Aldrich), orthovanadate (Sigma-Aldrich). We purchased Live/dead backlight
viability assay (Life Technologies) and Hoechst 33342 (Life Technologies). We used all
reagents as received. We used the nanopure deionized (DI) water (18 MΩ water,
Barnstead) to rinse glassware and prepare all solutions including standard LB medium
(1% tryptone peptone, 0.5% yeast extract, and 0.5% NaCl, pH = 7.2). We purchased
cell line of Escherichia coli, WT w3110 (MsbA) from Coli Genetic Stock Center (CGSC).

Cell Culture and Preparation
Gram-negative E. coli (MsbA) strain cells were cultured in an Erlenmeyer flask
containing 10 mL of L-Broth (LB) medium (1% tryptone peptone, 0.5% yeast extract,
and 0.5% NaCl, pH = 7.2) in an incubated floor shaker (Thermo Scientific, MaxQ5000;
160 rpm, 37 °C). After 12 h incubation, we inoculated 3 mL of pre-cultured cells into 10
mL of the LB medium in an Erlenmeyer flask. We then incubated the flask in the shaker
(160 rpm, 37 °C) for another 8 h. We harvested the cultured cells using centrifugation
(Beckman Model J2-21 Centrifuge, JA-14 rotor, at 7500 rpm, 23 °C, 10 min), washed
the cells with the PBS buffer (0.5 mM phosphate buffer, 1.5 mM NaCl, pH 7.0) three
times, and finally re-suspended the cells in the buffer. The final concentration of the
cells was adjusted to OD600 nm = 0.7 and used for the entire study.

Imaging of Single NPs in Single Living Cells
We prepared the cell suspension (OD600 nm = 0.7) containing 0.7 nM and 1.4 nM
AgMUNH-Oflx NPs or AgMUNH2 NPs (control NPs without ofloxacin) in the presence
and absence of orthovanadate (25 µM). The timer was started to record the incubation
time as NPs were added into the cell suspension.
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We sampled the mixture (1 µL) into a freshly prepared micro-chamber created by
nail polish and imaged the cells on 18 representative locations using DFOMS equipped
with a CCD camera and a digital color camera every 25 min (7 min for the slide
preparation and 18 min for imaging). We acquired LSPR spectra of single intracellular
and extracellular NPs in real time, which enabled us to identify and locate positions of
single NPs simultaneously.
The design and construction is fully explained in our previous studies.9, 12-14, 25, 2830, 42-43, 58-59, 61-62, 75, 78

In particular, our dark-field optical microscope was equipped with a

dark-field condenser (oil 1.43-1.20, Nikon), a 100x objective (Nikon Plan fluor 100x oil,
iris SL N.A. 0.5-1.3, W.D.0.20 mm), a charge coupled device (CCD) camera (Micromax,
Roper Scientific), a digital color camera (Handycam, Sony) and a multispectral imaging
system (Nuance, Cambridge Research Inc.).42-43 We have achieved high temporal
resolution up to 5 ms to continuingly image of transport of single NPs in and out of
single living cells.9, 14 However, we acquired images in every 1 min as we found that the
transport of single NPs in and out of single living cells was not a rapid process. 9,

14

Thus, a temporal resolution of minutes was sufficient to study transport of single NPs in
real time.
We prepared a fresh micro-chamber every 25 min and imaged single cells for 18
representative locations. This approach allowed us to study transport of single NPs in
massive numbers of cells (1500 cells) for each sample to make data adequate for
probing accumulation rates of bulk cells at a single cell resolution. We quantified
intracellular NPs and plotted them versus incubation time and determined the
accumulation rates (slopes of the plots) of single NPs in the cells over time.

Real-time Imaging of Viability of Single Cells
At the end of each experiment (2 h), we characterized the viability of the cells at
a single cell resolution using live/dead BacLight viability and counting assay.

We

imaged cells in a micro-chamber using dark-field optical microscopy and epifluorescence microscopy and counted the green fluorescence cells (peak wavelength of
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fluorescence spectra of SYTO9, λmax = 520 nm) and the red fluorescence cells (peak
wavelength of fluorescence spectra of propidium iodide, λmax = 610 nm) as live and
dead cells, respectively.

Fluorescence Spectroscopy Measurement
The cells in the PBS buffer were incubated with Hoechst 33342 (0.5 µM and 1
µM) with the presence and absence of orthovanadate (25 µM). Time-course
fluorescence intensity of the dye was measured at a 10-s data acquisition interval in real
time using a fluorescence spectrometer (Cary Eclipse). The excitation and emission
wavelengths were 354 and 478 nm, respectively.

Data Analysis and Statistics
We acquired eighteen representative locations of each cell suspension incubated
with 0.7 nM and 1.4 nM NPs every 25 min over 2 h and 5 min. Approximately fifteen
cells were acquired in a single CCD image simultaneously. Therefore, approximately
300 cells were imaged every 25 min and 1500 cells were studied over 2 h and 5 min for
each measurement. We repeated each experiment three times. Thus, we studied 4500
cells for each sample allowing us to gain sufficient statistics to study efflux function of
bulk cells at single cell resolution. We analyzed the numbers of intracellular NPs in 900
cells (300 cells per each measurement) at every 25 min and plotted them over time to
determine the accumulation rates (slopes of the plots) of intracellular NPs of both
AgMUNH-Oflx NPs and AgMUNH2 NPs in the cells in the presence and absence of
orthovanadate (25 µM) NPs at 41.5 min incubation. We performed statistical analysis
(2-sample t-test) using SPSS to compare means of intracellular NPs in the treated cells.
A minimum of 150 cells incubated with each type of NPs after each experiment
were studied cellular viability. We repeated each measurement three times. Therefore,
450 cells were assayed for each sample.
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CHAPTER IV

PROBING OF EFFLUX MECHANISMS OF MULTIDRUG ABC MEMBRANE
TRANSPORTERS IN SINGLE LIVE ESCHERICHIA COLI CELLS USING SIZEDEPENDENT PLASMONIC ANTIBIOTIC DRUG NANOCARRIERS

INTRODUCTION
The ATP-binding cassette (ABC) transporters are highly conserved proteins
found in both prokaryotes and eukaryotes.3, 8, 20 These membrane proteins couple ATP
hydrolysis to the active transport of various structurally and functionally unrelated
substances (e.g., drugs, ions, sugars and lipids) against their concentration gradients
across cell membrane.5, 8, 20 The extrusion of a wide variety of drugs, such as antibiotics
and chemotherapeutic agents leads to the ineffective treatments and multidrug
resistance (MDR).4,
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These major impacts underscore an urgency of a better

understanding of MDR mechanisms aiming to develop more effective drugs and avoid
MDR.
The ABC transporters are commonly composed of four core structure domains:
two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs).3, 5, 78

The TMDs which contain predominantly structural divergence within the various

subgroups of ABC transporters to define the large diversity of substrate specificity, form
the transmembrane channel for substrates to cross the membrane. The NBDs is more
highly conserved empower the transporters by coupling ATP hydrolysis leading to the
extrusion of the substrates out of the cells against concentration gradients. 3,

5-8

This

process is named as efflux function. The MsbA is an essential ABC transporter in Gramnegative

bacteria

lipopolysaccharide.5,

such
8, 10

as

Escherichia

coli

that

transports

lipid

A

and

In bacterial MsbA, a TMD is fused to an NBD in a half-

transporter that then homodimerizes to form the full transporter. 5 MsbA is a poly-specific
transporter which can recognize and transport a wide spectrum of drug molecules. 1, 10, 41
Interestingly, MsbA from E. coli shares significant protein sequence identity with
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mammalian multidrug resistance proteins (Pgp, ABCB1, MDR1) that are essentially
associated with resistance of anticancer drugs in human.5
A central question for ABC transporters to understand the underlying
mechanisms how they can extrude a wide variety of structurally unrelated substrates is
still unclear despite the increasing number of X-ray crystal and cryo-EM structures. The
X-ray crystallography and cryo-EM are the primary techniques to depict the structures of
membrane transporters at an atomic resolution; however, they cannot provide real-time
dynamic information.2, 71-73 For example, how do the efflux pumps sense such a wide
range of diverse substrates? How quickly do the pumps recognize the substrates and
extrude them out of the cells?
Radioisotopes and fluorescence dyes are widely used as substrates in the study
of efflux kinetics of membrane transporters in bulk cells. 8-12 Though these methods can
monitor the accumulation of substrates in real time, the results represent the average
behavior of a massive number of bulk cells and could mask rare interesting events as
individual cells have their independent efflux kinetics.13,

32

Besides, radioisotopes and

fluorophores do not process distinctive size-dependent physicochemical properties
therefore they are incapable of providing size information of membrane transporters and
are unsuitable to serve as various size-dependent pump substrates for the study of
efflux function of single membrane transporter in single live cells in real time.
Noble metal nanoparticles (e.g., silver nanoparticles, Ag NPs) process distinctive
size-dependent photostable plasmonic optical properties which show high dependence
on their sizes, shapes, dielectric constants and surrounding environments. 23-24,
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We

have demonstrated that we can use superior size-dependent LSPR and photostable
single Ag NPs as optical probes to study the size-dependent efflux kinetics of multidrug
membrane transporters in single live cells in real time for any desired period using darkfield optical microscopy and spectroscopy (DFOMS).9, 13-14, 29, 33, 59, 61, 76, 80-82 We have
systematically studied the dependence of the accumulation of substrates and efflux
function on the sizes, charges, chemicals, and bacterial strains of Gram-positive
bacteria (BmrA in Bacillus subtilis) and Gram-negative bacteria (MexAB-OprM in
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Pseudomonas aeruginosa) using bare and surface-functionalized NPs to mimic various
sizes of antibiotics (drugs) with modified surface properties (drug functional groups).9, 1314, 29, 33, 59, 61, 76, 80-82

In this study, we used size-dependent LSPR (color) AgMUNH-Oflx NPs
containing 9.4 x 103 Oflx molecules/NP46 and AgMUNH2 NPs (control NPs without Oflx)
with a diameter of 13.0 ± 3.1 nm to probe efflux function of single MsbA membrane
transporters in single live cell E. coli aiming to study their substrate-dependent
accumulation and efflux function. We previously reported substrate-dependent efflux
function of MsbA on the smaller sized AgMUNH-Oflx NPs (2.4 ± 0.7 nm). Therefore, this
study offers a possibility to compare efflux kinetics of MsbA membrane transporters
responded to different sized antibiotic optical probes to investigate whether types and
sizes of substrates play a pivotal role in the selective extrusion of efflux pumps. Insights
into the molecular basis of multidrug membrane transporters could guide us to a better
design of drugs that provide higher efficacy and more importantly can combat MDR.

RESULTS AND DISCUSSION
Real-time Imaging of Single NPs inside and outside Single Live Cells
We synthesized, purified and characterized antibiotic drug nanocarriers
(AgMUNH-Oflx NPs) by functionalizing AgMUNH2 NPs (13.0 ± 3.1 nm) with ofloxacin
(Oflx) to have 9.4 x 103 Oflx molecules/NP, as previously described.46 We used the
distinctive LSPR spectra (color) of single Ag NP-based nanocarriers to probe efflux
kinetics of MsbA multidrug membrane transporters as the cell membrane and debris do
not process plasmonic properties and appear white under dark-field illumination.
Furthermore, single Ag NPs are photostable,43 unlike fluorescence probes, allowing us
to probe efflux function of multidrug membrane transporters using antibiotic drug
nanocarriers over time. We incubated the cells (OD600

nm

= 0.7) with antibiotic drug

nanocarriers (AgMUNH-Oflx NPs) or control nanocarriers (AgMUNH2 NPs) and tracked
single nanocarriers in and out of single living cells in real time using DFOMS.
Representative dark-field optical images of the single live cells (WT) (Figure 21, 22: A)
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with single intracellular (Figure 21B, 22B: a) and extracellular NPs (Figure 21B, 22B: b)
show cross-sections of single rod-shaped bacterial cells with 2 µm in length and 0.5 µm
in width. As explained previously, we can image the thin-layer section of single cells
with single NPs using DFOMS because the membranes of single live cells above and
below the focal plane (190 nm depth of field) are invisible under dark-field illumination.9,
12-14, 28-29, 33

As the dark-field illumination penetrates the cell membrane to radiate intracellular
NPs, scattering of the NPs is required to transmit through the cell membrane to reach
the detector. However, the cell membrane absorbs photons making the intracellular NPs
blurry, dimmer and exhibit lower scattering intensity (Figure 21B, 22B: a). On the
contrary, the extracellular NPs show higher scattering intensity as they include
scattering intensity from both the NPs and the cell membrane. We have validated that
these distinctive properties of NPs could be used to distinguish intracellular NPs and
extracellular NPs to study efflux function of multidrug membrane transporters in single
live cells in real time. We use this approach to determine the intracellular AgMUNH-Oflx
NPs (Figure 21B: a) which are dimmer and exhibit lower scattering intensity than the
extracellular AgMUNH-Oflx NPs (Figure 21B: b), the same as those observed in the
AgMUNH2 NPs (Figure 22B: a, b). The representative LSPR spectra of single AgMUNHOflx NPs (i – iii) in Figure 21C show the peak wavelength and full-width-at-half-maxima
(FWHM) at 557 (128), 565 (126), and 578 (109) nm, respectively. In addition, the
representative LSPR spectra of single AgMUNH2 NPs (i – iii) in Figure 22C show the
peak wavelength and FWHM at 554 (124), 557 (96), and 565 (101) nm, respectively.
Note that the peak wavelengths of individual AgMUNH2 NPs are possibly at the longer
wavelength than those of the AgMUNH-Oflx NPs. This might be because of the size
distribution of the NPs ranging from 6 to 20 nm46 and the sizes of these individual
AgMUNH2 NPs could be larger than these individual AgMUNH-Oflx NPs. We observed
multiple AgMUNH2 NPs entered individual cells and they were not aggregated. We
would have detected the huge red-shift of LSPR spectra (changed color) and a much
higher of scattering intensity of the single NPs if the NPs became aggregated and their
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Figure 21. Imaging of single intracellular and extracellular 13.0 ± 3.1 nm AgMUNHOflx NPs in single living E. coli cells using DFOMS.
(A) The representative optical image of bacterial cells incubated with 1.4 nM AgMUNHOflx NPs showing intracellular and extracellular NPs as squared. (B) Zoom in optical
color (i and iii) and CCD (ii and iv) images of single cells show (a) intracellular and (b)
extracellular NPs which are pseudo colored in color images. The scale bar in A and B
are 10 and 2 µm, respectively. (C) LSPR spectra of representative single 13.0 ± 3.1 nm
AgMUNH-Oflx NPs (i-iii) show peak wavelengths and full width at half maximum
(FWHM) at 557 (128), 565 (126), and 578 (109) nm, respectively.
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Figure 22. Imaging of single intracellular and extracellular 13.0 ± 3.1 nm AgMUNH2
NPs in single living E. coli cells using DFOMS.
(A) The representative optical image of bacterial cells incubated with 1.4 nM AgMUNH2
NPs showing intracellular and extracellular NPs as squared. (B) Zoom optical color (i
and iii) and CCD (ii and iv) images of single cells show (a) intracellular and (b)
extracellular NPs which are pseudo colored in color images. The scale bar in A and B
are 10 and 2 µm, respectively. (C) LSPR spectra of representative single 13.0 ± 3.1 nm
AgMUNH2 NPs (i-iii) show peak wavelengths and full width at half maximum (FWHM) at
554 (124), 557 (96), and 565 (101) nm, respectively.
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sizes were larger. Taken together, we have successfully used plasmonic features of Ag
NP-based antibiotic drug nanocarriers (AgMUNH-Oflx NPs) and control nanocarriers
(AgMUNH2 NPs) to characterize single nanocarriers, determine their numbers, and
monitor them in situ in real time as they transport in and out the cellular membrane over
time.

The Dependence of Efflux Function of Single Live Cells on the Pump Inhibitor
We studied the accumulation rates of the antibiotic drug nanocarriers (AgMUNHOflx NPs) and the same sized control nanocarriers (AgMUNH2 NPs) in live MsbA (WT)
cells in the presence of a pump (ATPase) inhibitor, orthovanadate to determine whether
the NPs are substrates of MsbA membrane transporters in which they are responsible
for the efflux of the nanocarriers. The results in Figure 23A, B: b and Table 4 show that
the cells accumulate the intracellular NPs over time. The accumulation rates of
intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs during their incubation with 1.4 nM
NPs over 41.5 min are 1.11 and 27.42 intracellular NPs/min, respectively (Table 4). We
further study the effects of a pump (ATPase) inhibitor, orthovanadate on MsbA which is
an ATPase40 to determine whether MsbA membrane transporters are specifically
responsible for the efflux of the nanocarriers. The results in Figure 23A and Table 4
show the accumulation rate of the AgMUNH-Oflx NPs in the cells increases much more
rapidly from 1.11 to 2.09 NPs/min when orthovanadate is presence. The number of
intracellular AgMUNH-Oflx NPs significantly increase after the MsbA pumps are
inhibited (p < 0.0005). In contrast, the number of intracellular AgMUNH 2 NPs is
insignificantly different in the presence and its absence of orthovanadate (p = 0.636)
and the accumulation rates of intracellular AgMUNH2 NPs remain essentially
unchanged at 27.42 and 27.87 NPs/min, respectively (Figure 23B). The high
dependence of accumulation rates of only intracellular AgMUNH-Oflx NPs not
AgMUNH2 NPs on the MsbA pump function in the presence of orthovanadate suggests
that the AgMUNH-Oflx NPs are substrates of MsbA (WT) which is indeed responsible
for the extrusion of the intracellular AgMUNH-Oflx NPs. Moreover, the results (Figure
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Figure 23. Study of effects of a pump (ATPase) inhibitor, orthovanadate on the
accumulations of single 13.0 ± 3.1 nm AgMUNH-Oflx NPs and AgMUNH2 NPs.
(A) Plots of number of intracellular AgMUNH-Oflx NPs (A) and AgMUNH2 NPs (B) over
time in the presence (a, solid) and absence (b, empty) of the inhibitor (25 µM). The
points represent the experimental measurements and the lines are added to guide the
trend. At each time point (25 min), 900 cells were analyzed. In (A), the p value of data
(a) and (b) is less than 0.0005 (<0.0005), showing the significant difference of
intracellular NPs in the presence (a) and absence (b) of orthovanadate with 95%
confidential level, and the dependence of accumulation kinetics of AgMUNH-Oflx NPs
on the pump inhibitor.
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23B and Table 4) suggest that the AgMUNH2 NPs ineffectively be extruded out of the
cells by the MsbA membrane transporters. The efflux pumps could take long time to
recognize and extrude the NPs out as the number of intracellular AgMUNH 2 NPs in the
absence of orthovanadate start to decrease after 90 min (Figure 23B: b).
The size of antibiotic drug nanocarriers are order of magnitude larger than those
of conventional antibiotics. However, the results in Figure 23A are similar to those
observed using a fluorescence dye (Hoechst 33342) reported previously,35 indicating
that the AgMUNH-Oflx NPs did not cause steric effects and they are suitable substrates
for probing efflux function of single MsbA membrane transporters in single live cells.
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Table 4. Summary of Accumulation Rates and Numbers of Intracellular Single
13.0 ± 3.1 nm NPs in Single Living E.coli Cells.

Types of NPs
AgMUNH-Oflx

AgMUNH2

C Ag NPs

Inhibitor a

Accumulation rate

Numbers of

(nM)

(µM)

(NPs min-1) b

intracellular NPs c

0.7

0

0.41

17

1.4

0

1.11

46

1.4

25

2.09

87

0.7

0

12.23

508

1.4

0

27.42

1138

1.4

25

27.87

1156

a

Orthovanadate;

b

Accumulation rates (slopes of the plots) at the 41.5 min incubation;

c

Numbers of intracellular NPs accumulated in 900 live cells at the 41.5 min incubation.
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The Dependence of Efflux Function of NP Substrates on Their Type and Size in
Single Live Cells
To further study how the ABC membrane transporters could extrude a wide
variety of structurally and functionally unrelated substances, we studied the dependence
of the accumulation of intracellular NPs in single live cells upon types and sizes of NPs.
The numbers of intracellular AgMUNH2 NPs is significantly higher than those of the
AgMUNH-Oflx NPs in the absence and its absence of orthovanadate (p < 0.0005)
(Figure 23 and Table 4). We observed much higher accumulation rates of the
AgMUNH2 NPs (27.42 NPs/min) in single live cells than those of the AgMUNH-Oflx NPs
(1.11 NPs/min) over 41.5 min. These results suggest a strong dependence of efflux
function on types of substrate which MsbA membrane transporters possibly be
equipped with a sensing machinery for selectively detect and recognize noxious
substrates (e.g., conjugated Oflx molecules) and then extrude them out of the cells.
Interestingly, 13.0 ± 3.1 nm AgMUNH2 NPs accumulate in the cells 12 times more
rapidly than 2.4 ± 0.7 nm AgMUNH2 NP, suggesting size-dependent efflux kinetics of
AgMUNH2 NPs and the ABC membrane transporters could extrude 13.0 ± 3.1 nm
AgMUNH2 NPs at their least efficiency.
Furthermore, we compare the number of intracellular AgMUNH-Oflx NPs with a
diameter of 2.4 ± 0.7 nm with those of 13.0 ± 3.1 nm in the cells treated with 1.4 nM
NPs to study the size-dependent accumulation of single nanocarriers in single live cells.
Notably, the numbers of intracellular AgMUNH-Oflx NPs with a diameter of 2.4 ± 0.7 nm
and 13.0 ± 3.1 nm are insignificantly different and their accumulation rates of
intracellular AgMUNH-Oflx NPs are 1.03 and 1.11 NPs/min, respectively. When
orthovanadate is absence, the number of intracellular NPs of both sized AgMUNH-Oflx
NPs is not significantly different (0.7 nM, p = 0.29 and 1.4 nM, p = 0.738) but when
orthovanadate is present, the number of intracellular NPs of the smaller AgMUNH-Oflx
NPs is significantly higher than that of the larger sized AgMUNH-Oflx NPs (p = 0.004).
These results suggest size-dependence of the efflux kinetics of single nanocarriers in
MsbA in which efflux pumps extrude the small AgMUNH-Oflx NPs more effectively since
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there are more numbers of the smaller NPs retain inside the cells when the pump
function was inhibited.
We previously reported in Chapter II, that the MIC50 of the smaller nanocarriers is
approximately 4 times higher than that of the larger nanocarriers. This observation could
be attributed to the lower multivalent effects (higher binding affinity with the targets) of
the smaller nanocarriers and the ability of the cells to effectively extrude the smaller
nanocarriers out.

The Dependence of Efflux Function on NP Concentrations in Single Live Cells
We further studied the dependence of accumulation and efflux rates of antibiotic
drug nanocarriers (13.0 ± 3.1 nm AgMUNH-Oflx NPs) and the control nanocarriers
(AgMUNH2 NPs) upon their concentrations (0.7 and 1.4 nM), aiming to determine how
they enter the cells. The results in Figure 24 show that the number of intracellular of
both AgMUNH-Oflx NPs (Figure 24A) and AgMUNH2 NPs (Figure 24B) significantly
depends on NP concentrations (AgMUNH-Oflx NPs, p < 0.0005 and AgMUNH2 NPs, p <
0.0005). The accumulation rates of single AgMUNH-Oflx NPs and AgMUNH2 NPs
increase from 0.14 to 0.37 (2.6 times) and from 4.08 to 9.14 (2.2 times), respectively as
the concentration of NPs increases from 0.7 to 1.4 nM. The results in Figure 24 suggest
that NPs enter the cells via passive diffusion in which the NPs are driven by the
concentration gradient across the membrane.
We summarize quantitative accumulation rates of intracellular AgMUNH-Oflx
NPs and AgMUNH2 NPs in single living cells (Figure 23, 24) in Table 4. The results
demonstrate that AgMUNH-Oflx NPs and AgMUNH2 NPs are substrates of MsbA
membrane transporters and the cells accumulate intracellular AgMUNH 2 NPs at the
highest rate. We found the dependence of the accumulation rates on the type of
substrates, the pump inhibitor and the concentration of NPs.
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Figure 24. Study of the dependence of the accumulations of 13.0 ± 3.1 nm
AgMUNH-Oflx NPs and AgMUNH2 NPs on NP concentrations in living E. coli cells.
(A) Plots of number of intracellular AgMUNH-Oflx NPs in MsbA incubated with 1.4 nM
(a) and 0.7 nM (b) of 13.0 ± 3.1 nm AgMUNH-Oflx NPs versus time. (B) Plots of number
of intracellular AgMUNH2 NPs in MsbA incubated with 1.4 nM (a) and 0.7 nM (b) of 13.0
± 3.1 nm AgMUNH2 NPs versus time. The points represent the experimental
measurements and the lines are added for trend projection. Note that 900 cells were
analyzed at each point (every 25 min). In (A) and (B), the p values of data in (a) and (b)
are less than 0.0005 (<0.0005), indicating statistically significant difference of
intracellular NPs in the cell incubated with (a) 1.4 nM and (b) 0.7 nM at 95% confidential
level, and concentration dependent efflux functions of MsbA.
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Characterization of Viability of Single Cells
We characterized the viability of the cells (MsbA WT) to ensure that the doses of
the antibiotic drug nanocarriers (AgMUNH-Oflx NPs), the control nanocarriers
(AgMUNH2 NPs) and the pump inhibitor that we used to probe efflux function of E. coli
did not kill the cells and interfere with their pump function. At the end of the experiment,
we studied viability of the cells incubated with the antibiotic drug nanocarriers
(AgMUNH-Oflx NPs) or the control nanocarriers (AgMUNH2 NPs) with the presence and
absence of orthovanadate throughout the duration of the experiment over 2 h using
live/dead BacLight assay. We acquired optical and fluorescence images of single cells
using DFOMS and epifluorescence microscopy, respectively. We observed intracellular
and extracellular NPs using DFOMS and assay cellular viability using fluorescence
staining. The green SYTO9 fluorescence dye (λmax = 520 nm) penetrates to the cells
and stains cellular nucleic acids of the live cells while the red PI fluorescence dye (λmax =
610 nm) enter only the dead with compromised cell membrane integrity.
Representative optical images of the cells incubated with 1.4 nM AgMUNH-Oflx
NPs in the presence (Figure 25A: a) and absence (Figure 25B: a) of orthovanadate (25
µM) over 2 h show the cells with and without NPs. Viable cells emit green fluorescence
but not the red fluorescence as illustrated in Figure 25A: b and Figure 25B: b. We
determined the percentage of live and dead cells by dividing the number of viable cells
by the total number of cells. The results show that 99 % of the cells incubated with 1.4
nM AgMUNH-Oflx NPs in the presence and absence of orthovanadate (25 µM) (Figure
25C) are alive. Similarly, representative optical images of the cells incubated with 1.4
nM AgMUNH2 NPs in the presence (Figure 26A: a) and absence (Figure 26B: a) of
orthovanadate (25 µM) over 2 h show the cells with and without NPs. The cells emit
green fluorescence but not red fluorescence suggesting that they are alive (Figure 26A,
B: b). The results show that 99 % of the cells are alive (Figure 26C). As most of the cells
are alive, the accumulation rates of the NPs in single live cells are involved in the
passive diffusion process of NPs and efflux function of the membrane transporters but
not the compromised membrane integrity due to the cell death. The findings further
demonstrate that the doses (0.7 and 1.4 nM) of the AgMUNH-Oflx NPs are

81

A

a

b

B

a

b

120

% Viable Cells

C

a

b

80

40

0
MsbA with inhibitor

MsbA

Figure 25. Characterization of viability of single bacterial cells incubated with 13.0
± 3.1 nm AgMUNH-Oflx NPs using LIVE/DEAD BacLight viability and counting
assay.
In (A) and (B), representative dark field optical image (a) and fluorescence image (b) of
single bacterial cells (MsbA), incubated with 1.4 nM AgMUNH-Oflx in the presence (A)
and absence (B) of the inhibitor (25 µM) over the duration of each experiment for 2 h,
show that the cells with intracellular NPs (as squared) or without NPs emit the green
fluorescence (λ

max

= 520 nm) of SYTO9, indicating that cells are viable. (C) Plots of

percentage of viable cells (a) and dead cells (b) of MsbA incubated with 1.4 nM
AgMUNH-Oflx with and without the inhibitor, indicate that 99 % of the cells are alive.
Minimum 300 cells were assayed and analyzed. The scale bar is 5 µm.
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Figure 26. Characterization of viability of single bacterial cells incubated with 13.0
± 3.1 nm AgMUNH2 NPs using LIVE/DEAD BacLight viability and counting assay.
In (A) and (B), representative dark field optical image (a) and fluorescence image (b) of
single bacterial cells (MsbA), incubated with 1.4 nM AgMUNH2 in the presence (A) and
absence (B) of the inhibitor (25 µM) over the duration of each experiment for 2 h, show
that the cells with intracellular NPs (as squared) or without NPs emit the green
fluorescence (λ

max

= 520 nm) of SYTO9, indicating that cells are viable. (C) Plots of

percentage of viable cells (a) and dead cells (b) of MsbA incubated with 1.4 nM
AgMUNH2 with and without the inhibitor, indicate that more than 99 % of the cells are
alive. Minimum 300 cells were assayed and analyzed. The scale bar is 5 µm.
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biocompatible and suitable for the study of mechanisms related to MDR and efflux
function of multidrug membrane transporters in bacterial cells such as E. coli.

SUMMARY
We used LSPR spectra (color) of the AgMUNH2 NPs (absence of Oflx) and the
AgMUNH-Oflx NPs containing 9.4x103 of Oflx molecules per NP to identify and monitor
single NPs in the study of efflux function and kinetics of MsbA (ABC) membrane
transporters in single live cells in real time. The NPs up to 1.4 nM are biocompatible to
the cells over 2 h of experimental duration. We found the concentration dependence of
the accumulation rates of the AgMUNH-Oflx NPs and AgMUNH2 NPs indicating that the
passive diffusion driven by concentration gradients is the main mechanism for the NPs
to transport into the cells. Interestingly, we found effects of the pump inhibitor
(orthovanadate) only on the accumulation rate of AgMUNH-Oflx NPs which increases in
the presence of the inhibitor. In contrast, the accumulation rates of AgMUNH 2 NPs in
the presence and absence of orthovanadate are the same (9 NPs/min) and much higher
than those of the AgMUNH-Oflx NPs. These results suggest that substrate-dependent
efflux function of MsbA membrane transporters in which they could be equipped with a
sensing machinery to detect, recognize and extrude toxic substrates (e.g., antibiotics
and chemotherapeutic agents). Notably, the efflux pumps ineffectively extrude the
AgMUNH2 NPs and this process starts after 90 min of incubation suggesting that the
efflux pumps might take a long time to sense the AgMUNH2 NPs. Moreover, we found
size-dependent accumulation rates of intracellular AgMUNH-Oflx NPs with a diameter of
2.4 ± 0.7 nm and 13.0 ± 3.1 nm. The cells could extrude the smaller nanocarriers more
effectively than the larger nanocarriers. Taken together, this study demonstrates that
single AgMUNH-Oflx NPs and AgMUNH2 NPs could be used as optical imaging probes
for study of size- and substrate-dependent efflux function of MsbA (ABC) membrane
transporters in bacterial cells because they process size-dependent LSPR spectra and
contain conjugated drug molecules on the surface that exhibit bactericidal effects.
Results from this study also suggest an evidence that multidrug membrane transporters
could have a sensing machinery to screen for toxic substrates.

Insights into the
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molecular basis of efflux mechanisms how multidrug membrane transporters could
extrude a wide variety of substrates will lead to better understandings and a feasibility of
a design of better drugs that could potentially avoid MDR in pathogenic bacterial cells,
such as E. coli.

MATERIALS AND METHODS
Reagents and Cell Line
We purchased sodium chloride, sodium phosphate (Sigma-Aldrich), sodium
phosphate monobasic monohydrate (Sigma-Aldrich), bacto-tryptone and yeast extract
(Sigma-Aldrich), orthovanadate (Sigma-Aldrich). We purchased Live/dead backlight
viability assay (Life Technologies) and Hoechst 33342 (Life Technologies). We used all
reagents as received. We used the nanopure deionized (DI) water (18 MΩ water,
Barnstead) to rinse glassware and prepare all solutions including standard LB medium
(1% tryptone peptone, 0.5% yeast extract, and 0.5% NaCl, pH = 7.2). We purchased
cell line of Escherichia coli, wt w3110 (MsbA) from Coli Genetic Stock Center (CGSC).

Cell Culture and Preparation
Gram-negative E. coli (MsbA) strain cells were pre-cultured in an Erlenmeyer
flask containing 10 mL of L-Broth (LB) medium (1% tryptone peptone, 0.5% yeast
extract, and 0.5% NaCl, pH = 7.2) in an incubated floor shaker (Thermo Scientific,
MaxQ5000; 160 rpm, 37 °C) for 12 h. We then inoculated 3 mL of pre-cultured cells into
10 mL of fresh LB medium in an Erlenmeyer flask. We then incubated the flask in the
shaker (160 rpm, 37 °C) for an additional 8 h. We harvested the cultured cells using
centrifugation (Beckman Model J2-21 Centrifuge, JA-14 rotor, at 7500 rpm, 23 °C, 10
min), washed the cells with the PBS buffer (0.5 mM phosphate buffer, 1.5 mM NaCl, pH
7.0) three times, and finally re-suspended the cells in the PBS buffer. The final
concentration of the cells was adjusted to OD600 nm = 0.7 and used for the entire study.
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The real-time study of efflux function of membrane transporters in bacterial cells
has been always conducted in PBS buffer but not in cell culture medium which would
lead to the cell growth and creation of the cells with different growth stages.9, 12-14, 28-29, 33
It is crucial to study efflux function of membrane transporter at a constant cell
concentration and a certain cellular stage in order to compare results among other
experiments. Our previous studies have demonstrated that the cells suspended in the
PBS buffer retain their efflux function over hours and they are suitable for the study of
efflux function.9, 12-14, 28-29, 33

Real-time Imaging of Single NPs inside and outside Single Living Cells and
Characterization of Cellular Viability
We prepared cell suspension (OD600

nm

= 0.7) containing 0.7 nM and 1.4 nM

AgMUNH-Oflx NPs or AgMUNH2 NPs (control NPs without ofloxacin) in the presence
and absence of orthovanadate (25 µM). We started a timer simultaneously as we added
NPs into the cell suspension.
After the sample prepared, we sampled the mixture (1 µL) into a freshly prepared
micro-chamber created by nail polish and continuously imaged the cells on 18
representative locations using DFOMS equipped with a CCD camera and a digital color
camera every 25 min (7 min for the slide preparation and 18 min for imaging). We
imaged the transport of single nanocarriers moving in and out of single cells in real time
using DFOMS equipped with CCD camera (Micromax, Roper Scientific), digital color
camera (Handycam, Sony) and multispectral imaging system (Nuance, Cambridge
Research Inc.).

9, 14, 25, 58, 62

described previously.9,

The design and construction of DFOMS have been fully

13-14, 25-26, 28-29, 32-33, 43, 58-59, 61-62, 76, 80-82

Our dark-field optical

microscope was equipped with a dark-field condenser (oil 1.43-1.20, Nikon) and a 100x
objective (Nikon Plan fluor 100x oil, iris SL N.A. 0.5-1.3, W.D.0.20 mm) with a depth of
field of 190 nm. Although we have achieved high temporal resolution up to 5 ms to
continuingly image for tracking the transport of single NPs, we acquired images in every
1 min since we found that the transport of single NPs in and out of single living cells was
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not a rapid process and a temporal resolution of minutes was sufficient to study
transport of single NPs in real time.9, 14
We sampled the mixture and re-prepared a fresh micro-chamber every 25 min
and imaged single cells for 18 representative locations for 2 h. By using this approach,
we could acquire sufficient data from massive numbers of cells (1500 cells) for each
sample for probing the accumulation rates of bulk cells at a single cell resolution. We
quantified intracellular NPs and plotted them versus incubation time and determined the
accumulation rates (slopes of the plots) of single NPs in the cells over time.
The viability of cells was characterized at a single cell resolution using
LIVE/DEAD BacLight viability and counting assay at the end of each experiment (2 h).
We imaged cells in the micro-chamber using dark-field optical microscopy and epifluorescence microscopy and counted the green fluorescence cells stained by SYTO9
(λmax = 520 nm) and the red fluorescence cells stained by propidium iodide (λmax = 610
nm) as live and dead cells, respectively.

Data Analysis and Statistics
Cells were imaged for eighteen representative locations of each cell suspension
containing 0.7 nM and 1.4 nM NPs in a presence or absence of orthovanadate every 25
min over 2 h and 5 min. Approximately fifteen cells were acquired in a single CCD
image simultaneously. Therefore, approximately 300 cells were imaged every 25 min
and 1500 cells were studied over 2 h and 5 min for each measurement. We repeated
each experiment three times. Thus, we studied 4500 cells for each sample allowing us
to gain sufficient statistics to study efflux function of bulk cells at a single cell resolution.
We analyzed the numbers of intracellular NPs in 900 cells (300 cells per each
measurement) at every 25 min and plotted them over time to determine the
accumulation rates (slopes of the plots) of intracellular NPs of both AgMUNH-Oflx NPs
and AgMUNH2 NPs for the cells in the presence and absence of orthovanadate (25 µM)
at 40.5 min incubation time when the accumulation of NPs reach a plateau and
essentially remain stable. We performed statistical analysis (2-sample t-test) using
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SPSS to compare means of intracellular NPs in the treated cells. We studied the
viability of single cells at a minimum of 150 cells that were incubated with each type of
NPs after each experiment (2 h). We repeated each measurement three times.
Therefore, 450 cells were assayed for each sample.
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CHAPTER V

STUDY OF SUBSTRATE- AND SIZE-DEPENDENT EFFLUX FUNCTION OF
MULTIDRUG ABC MEMBRANE TRANSPORTERS IN SINGLE LIVE
ESCHERICHIA COLI CELLS USING ANTIBIOTIC DRUG NANOCARRIER
OPTICAL PROBES

INTRODUCTION
ATP-binding cassette (ABC) membrane transporters (efflux pumps) is a large
protein family found in all prokaryotic and eukaryotic cells. 3,

7, 83

They mediate the

uptake of nutrients and the export of a wide variety of substances across cellular
membrane such as peptides, lipids and drugs.3, 5, 7, 83 These efflux pumps protect cells
(e.g., bacteria and cancer cells) from many cytotoxins such as antibiotics and anticancer
drugs, conferring multidrug resistance (MDR).3,

5, 7, 83-84

Efflux systems are currently

thought to be responsible for MDR in bacteria and cancer cells which greatly causes
ineffective treatments of infections and cancers.4, 79, 84
Despite a large number of structurally unrelated substrates, the ABC transporters
have common four core domains: two transmembrane domains (TMDs) and two
nucleotide-binding domains (NBDs).3, 5, 7, 83 The TMDs consist of the large diversity of
specific binding sites and multiple membrane-spanning proteins which together form the
pathway through, which the transported substrate crosses the lipid bilayer, whereas the
NBDs couple conformation changes induced by ATP binding and hydrolysis. 3,

5, 7, 83

MsbA is an essential ABC membrane transporters in Gram-negative bacteria (e.g.,
Escherichia coli) and play a key role in transport of lipid A and lipopolysaccharide (LPS)
from the cytoplasmic leaflet (inward-facing) to the periplasmic leaflet (outward-facing) of
bacterial inner membrane by utilizing ATP energy.1-2, 83 Functional studies have reported
that MsbA could recognize and extrude a wide spectrum of antibiotics causing
resistance to certain antibiotics.1, 10, 41
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Currently, the primary techniques to depict the structures of membrane
transporters at the atomic resolution are X-ray crystallography and cryo-EM.2,

71-73

Though the number of available X-ray crystal and cryo-EM structures of ABC
membrane transporters is increasing, the molecular basis of efflux mechanisms, and
how the similar structural membrane transporters could extrude diverse structurally
unrelated substrates has not yet fully understood. These techniques cannot provide
real-time dynamic insights into how the efflux pumps selectively detect and recognize
various types of substrates before extruding them out of the cells.
Conventional methods to study MDR include measurements of the accumulation
of radioisotopes (14C and 3H) or fluorescence dyes as they diffuse into the cells and are
extruded by prokaryotic and eukaryotic cells over time.9-12, 83 These approaches provide
efflux kinetics of the bulk cells and they could mask any rare interesting event since
individual cells behave differently emphasizing the importance to probe efflux kinetics of
individual membrane transporters in single live cells in real time. 9,

14

Moreover, single

radioisotopes and fluorophores themselves do not process distinctive size-dependent
physiochemical properties. Therefore, these conventional probes could not serve as
various size-dependent pump substrates for the study of efflux function of single
membrane transporters in single live cells.
Nobel metal nanoparticles (e.g., Ag NPs) process distinctive plasmonic
properties, which highly depend on their sizes, shapes, dielectric constant, and
surrounding environments.23-24 Single Ag NPs have high Rayleigh scattering enables us
to image and characterize them under illumination of halogen lamps using dark-field
optical microscopy and spectroscopy (DFOMS).14, 25-27 We have demonstrated that we
can use superior size-dependent LSPR and photostable single Ag NPs as optical
probes to study the size-dependent efflux kinetics of multidrug membrane transporters
in single live cells in real time.9, 13-14, 28-29 In the previous studies, we have used bare Ag
NPs and surface modified Ag NPs to study the dependence of transport kinetics and the
accumulation of substrates on the sizes, charges, chemicals, and bacterial strains of
Gram-positive bacteria (BmrA in Bacillus subtilis)9,
(MexAB-OprM in Pseudomonas aeruginosa).14, 31-33

13, 29-30

and Gram-negative bacteria
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In this study, we explored substrate-dependent accumulation and efflux function
of single MsbA membrane transporters in single live E. coli cells using size-dependent
LSPR (color) AgMUNH-Oflx NPs with a diameter of 92.6 ± 4.4 nm containing 6.5 x 105
Oflx molecules/NP and AgMUNH2 NPs (control NPs without Oflx). We previously
reported substrate-dependent efflux function of MsbA using the small and medium sized
AgMUNH-Oflx NPs (2.4 ± 0.7 and 13.0 ± 3.1 nm). Therefore, this study offers a
possibility to compare efflux kinetics of MsbA membrane transporters interacting to
different sized antibiotic optical probes to investigate whether types and sizes of
substrates play an important role in the selective extrusion of efflux pumps. To our
knowledge, systematic studies of the dependence of the accumulation rates of
substrates and efflux function of MsbA membrane transporters on the sizes of antibiotic
nanocarrier optical probes in single live cells have not yet been reported.

RESULTS AND DISCUSSION
Study of Efflux Kinetics of Membrane Transporters using Single Antibiotic Drug
Nanocarriers Optical Probes
We used the distinctive LSPR spectra (color) of single 92.6 ± 4.4 nm AgMUNHOflx NPs and AgMUNH2 NPs to probe efflux kinetics of MsbA multidrug membrane
transporters. These distinctive properties allow us to distinguish the NPs from the cell
membrane and other debris which do not process plasmonic properties and appear
white under dark-field illumination. We suspended the cells in a PBS buffer (0.5 mM
phosphate buffer saline with 1.5 mM, pH = 7.0), but not cell culture medium. The studies
of efflux function of membrane transporters in bacterial cells have been conducted in
the PBS buffer to maintain cell concentration and cellular growth stage over time
making results comparable to other experiments.

9, 13-14, 29-33

We incubated the cells

(OD600 nm = 0.7) with the AgMUNH-Oflx NPs or AgMUNH2 NPs and tracked single NPs
in and out of single live cells in real time using DFOMS. Representative dark-field
optical images of the single live cells (MsbA, WT) that were incubated with 3.7 pM
solution of AgMUNH-Oflx NPs (Figure 27A) and AgMUNH2 NPs (Figure 28A) show
cross-sections of single rod-shaped bacterial cells with 2 µm in length and 0.5 µm in
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width. As explained previously, we can image the thin-layer section of single cells with
single NPs using DFOMS since the membranes of single live cells above and below the
focal plane (190 nm depth of field) are invisible under dark-field illumination. Thus, NPs
on top or below membranes of the cells are out of the focal plane and do not appear
under dark-field illumination.
The scattering intensity of single NPs was used to identify whether they are
intracellular NPs or extracellular NPs. The intracellular NPs look blurry, dimmer, and
exhibit lower scattering intensity. The cell membrane absorbs photons from the darkfield illumination that penetrates through the cells to radiate intracellular NPs, reducing
the scattering intensity that can pass through the cells to reach a detector. In contrast,
the extracellular NPs show higher scattering intensity because they include scattering
intensity from both NPs and cell membrane. We have demonstrated the feasibility of
using the distinctive properties and scattering intensity of NPs to distinguish intracellular
NPs and extracellular NPs in the study efflux function of multidrug membrane
transporters in single live cells in real time.

9, 13-14, 29-33

Moreover, single Ag NPs show

superior photo-stability over fluorescence dyes, allowing us to probe efflux function of
multidrug membrane transporters using AgMUNH-Oflx NPs and AgMUNH2 NPs over
time. We used this validated approach to determine the intracellular AgMUNH-Oflx NPs
(Figure 27B: a) and AgMUNH2 NPs (Figure 28B: a) which are blurry, dimmer and exhibit
a lower scattering intensity than the extracellular AgMUNH-Oflx NPs (Figure 27B: b)
and AgMUNH2 NPs (Figure 28B: b), respectively. As mentioned in our previous studies,
9, 13-14, 29-33

we use their LSPR spectra (color) to characterize the size and determine the

number of single NPs in real time as they are incubated with the cells and transport in
and out across the cell membrane over time. The representative LSPR spectra of single
AgMUNH-Oflx NPs (Figure 27C) and AgMUNH2 NPs (Figure 28C) show the peak
wavelength and full width at half maxima (FWHM) at 641 (172) and 629 (215) nm,
respectively. Taken together, we have successfully used plasmonic features of
AgMUNH-Oflx NPs and AgMUNH2 NPs to characterize single NPs, determine their
numbers, and monitor them in situ in real time as they transport in and out across the
cellular membrane over time.
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Figure 27. Imaging of single intracellular and extracellular 92.6 ± 4.4 nm AgMUNHOflx NPs in single living E. coli cells using DFOMS.
(A) The representative optical image of bacterial cells incubated with 3.7 pM AgMUNHOflx NPs showing intracellular and extracellular NPs as squared. (B) Zoom in optical
color (i and iii) and CCD (ii and iv) images of single cells show (a) intracellular and (b)
extracellular NPs which are pseudo colored in color images. The scale bar in A and B
are 10 and 2 µm, respectively. (C) LSPR spectra of representative single 90nm
AgMUNH-Oflx NPs show peak wavelengths and full width at half maxima (FWHM) at
641 (172) nm.
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Figure 28. Imaging of single intracellular and 92.6 ± 4.4 nm AgMUNH 2 NPs in
single living E. coli cells using DFOMS.
(A) The representative optical image of bacterial cells incubated with 3.7 pM AgMUNH 2
NPs showing intracellular NPs as squared. (B) Zoom optical color (i and iii) and CCD (ii
and iv) images of single cells show (a) intracellular and (b) extracellular NPs which are
pseudo colored in color images. The scale bar in A and B are 10 and 2 µm,
respectively. (C) LSPR spectra of representative single 90nm AgMUNH2 NPs show
peak wavelengths and full width at half maxima (FWHM) at 629 (215) nm.
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Study of the Dependence of Efflux Function of MsbA Membrane Transporters on
the Pump Inhibitor
To study whether the membrane transporter (MsbA) is indeed responsible for the
efflux out of the drug nanocarriers out of living cells, we studied the accumulation rates
of the AgMUNH-Oflx NPs and AgMUNH2 NPs in live E. coli (MsbA, WT) cells in the
presence and absence of a pump (ATPase) inhibitor, orthovanadate (Na3VO4). The
inhibitor interferes with ATP hydrolysis which is the important step of the MsbA (ABC)
membrane transporters to extrude substrates out of the cells. 40,

83

Moreover,

prokaryotes (bacterial cells) do not have endocytosis, pinocytosis and exocytosis so
these processes are not involved in the transport of the NPs through cellular
membranes. The results in Figure 29A, B: b and Table 5 show that the cells accumulate
NPs over time. The accumulation rates of intracellular AgMUNH-Oflx NPs and
AgMUNH2 NPs during their incubation with 3.7 pM NPs over 41.5 min are 0.48 and 1.31
NPs/min, respectively. We further studied effects of the pump inhibitor on cellular efflux
function and determine whether MsbA is responsible for the extrusion of NPs by
incubating the cells with 3.7 pM NPs and orthovanadate (25 µM). The results in Figure
29A, B: a and Table 5 demonstrate that the accumulation rates of intracellular
AgMUNH-Oflx NPs and AgMUNH2 NPs is more rapidly in the presence of
orthovanadate which the accumulation rate of intracellular NPs during their incubation
with 3.7 pM NPs over 41.5 min increase from 0.48 to 1.10 and 1.31 to 2.21 NPs/min,
respectively. Orthovanadate hindered efflux function of MsbA leading to a significant
increasing of the number of intracellular NPs (p < 0.005).
The antibiotic nanocarrier optical probes used here are order of magnitude larger
than the conventional antibiotic. However, the accumulation rates of the NPs shown in
Figure 29 are very similar to those observed using a fluorescence probe (Hoechst
33342),35 suggesting that the large sizes of NPs and conjugated Oflx did not disrupt
their transport into the cells and their extrusion by the pumps. Thus, we can study the
size-dependent transport kinetics of multidrug efflux pumps of single live cells in real
time at a nanometer resolution using antibiotic drug nanocarrier optical probes.

95

# of Intracellular
AgMUNH-Oflx NPs

60

a

A
40

b
20

0
0

25

50
75
Time (min)

100

125

120

# of Intracellular
AgMUNH 2 NPs

B

a

80

b
40

0
0

25

50
75
Time (min)

100

125

Figure 29. Study of effects of a pump (ATPase) inhibitor, orthovanadate on the
accumulations of single 92.6 ± 4.4 nm AgMUNH-Oflx NPs and AgMUNH2 NPs.
(A) Plots of number of intracellular AgMUNH-Oflx (A) and AgMUNH2 (B) over time in
the presence (a, solid) and absence (b, empty) of the inhibitor (25 µM). The points
represent the experimental measurements and the lines are added to guide the trend.
At each time point (25 min), 900 cells were analyzed. In (A) and (B), the number of
intracellular NPs in (a) with the presence and (b) absence of orthovanadate are
significantly different (p<0.0005) at 95% confidential interval, showing the dependence
of efflux function of MsbA on the pump inhibitor.
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Table 5. Summary of Accumulation Rates and Number of Intracellular Single 92.6
± 4.4 nm NPs in Single Living E. coli Cells.

Types of NPs
AgMUNH-Oflx

AgMUNH2

C Ag NPs

Inhibitor a Accumulation rate

Numbers of

(pM)

(µM)

(NPs min-1) b

intracellular NPs c

1.85

0

0.22

9

3.7

0

0.48

20

3.7

25

1.10

46

1.85

0

0.61

26

3.7

0

1.31

54

3.7

25

2.21

92

a

Orthovanadate;

b

Accumulation rates (slopes of the plots) at the 41.5 min incubation;

c

Numbers of intracellular NPs accumulated in 900 live cells at the 41.5 min incubation.
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Probing of the Dependence of Accumulation of Intracellular Antibiotic Drug
Nanocarriers on Their Concentrations
We further studied the dependence of accumulation and efflux rates of antibiotic
drug nanocarriers (AgMUNH-Oflx NPs) and control nanocarriers (AgMUNH2 NPs) upon
their concentrations (1.85 and 3.7 pM), aiming to determine how they enter the cells and
compare the mechanism with those observed in conventional antibiotics. The results in
Figure 30 show that the number of intracellular AgMUNH-Oflx NPs (Figure 30A) and
AgMUNH2 NPs (Figure 30B) significantly depends on NP concentrations (p < 0.0005).
We summarize quantitative accumulation rates and the number of intracellular NPs in
living cells (Figure 29 and 30) in Table 5, which increase with the concentration of NPs,
vice versa. The accumulation rates of single AgMUNH-Oflx NPs and AgMUNH2 NPs
increased 2.2 times as the concentration of NPs increases from 1.85 to 3.7 pM,
suggesting that NPs enter the cells via passive diffusion in which the NPs are driven by
the concentration gradient across the membrane.

Study of the Dependence of Efflux Function of Membrane Transporters on Type
and Size of NP Substrates in Single Live Cells
We further studied the dependence of the accumulation rates of intracellular NPs
upon their types and sizes aiming to examine cellular mechanisms by which the ABC
membrane transporters could selectively extrude a wide variety of structurally unrelated
substances. In this study, we found the numbers of intracellular AgMUNH2 NPs is
significantly higher than those of the AgMUNH-Oflx NPs in both 1.85 and 3.7 pM (p <
0.0005) and the cells accumulated intracellular AgMUNH2 NPs 2.8 time more rapidly
than those of AgMUNH-Oflx NPs (Figure 30 and Table 5). Moreover, we previously
reported that the accumulation rates of bare Ag NPs with a diameter of 93 ± 13 nm in
Gram-positive bacteria (BmrA in Bacillus subtilis)29 and 91.0 ± 9.7 nm in Gram-negative
bacteria (MexAB-OprM in Pseudomonas aeruginosa)14 were 6.8 NPs/min within 10.5
min and 1.65 NPs/min within 32.5 min, respectively. In comparison, the cells extruded
AgMUNH-Oflx NPs much more rapidly than AgMUNH2 NPs and bare Ag NPs,
respectively.
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Figure 30. Study of the dependence of the accumulations of 92.6 ± 4.4 nm
AgMUNH-Oflx NP and AgMUNH2 NPs on NP concentrations in living E. coli cells.
(A) Plots of number of intracellular AgMUNH-Oflx NPs in MsbA incubated with 3.7 pM
(a) and 1.85 pM (b) of the AgMUNH-Oflx NPs versus time. (B) Plots of number of
intracellular Ag-MUNH2 NPs in MsbA incubated with 3.7 pM (a) and 1.85 pM (b) of the
AgMUNH2 NPs versus time. The points represent the experimental measurements and
the lines are added for trend projection. Note that 900 cells were analyzed at each point
(every 25 min). In (A) and (B), data (a) and (b) are significantly different (p<0.0005) at
95% confidential interval, showing the dependence of accumulation of intracellular NPs
on the NP concentration.
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Interestingly, we have observed these phenomena in the studies of efflux
function of MsbA membrane transporters using different sized antibiotic nanocarrier
optical probes suggesting a strong dependence of efflux function on types of substrate
which MsbA membrane transporters possibly be equipped with a sensing machinery for
selectively detect and recognize noxious substrates (e.g., conjugated Oflx molecules)
and then extrude them out of the cells.
Moreover, we compare the number of intracellular AgMUNH-Oflx NPs with a
diameter of 92.6 ± 4.4 nm with those of 13.0 ± 3.1 and 2.4 ± 0.7 nm in the cells to study
the size-dependent accumulation of single nanocarrier optical probes in single live cells.
We found that the numbers of intracellular AgMUNH-Oflx NPs with a diameter of 2.4 ±
0.7 nm and 13.0 ± 3.1 nm are insignificantly different, and their accumulation rates of
intracellular AgMUNH-Oflx NPs are 0.34 and 0.37 NPs/min, respectively. However, the
accumulation rate of 92.6 ± 4.4 nm AgMUNH-Oflx NPs is 0.16 NPs/min and it is much
lower than those of the smaller sized AgMUNH-Oflx NPs. These observations may be
attributed to the low membrane permeability and the low concentration gradients across
cell membrane of the largest nanocarriers (3.7 pM of 92.6 ± 4.4 nm nanocarriers versus
1.4 nM of 13.0 ± 3.1 and 2.4 ± 0.7 nm nanocarriers). We used the very low
concentrations of 92.6 ± 4.4 nm nanocarriers in the study of efflux function because
they are much more toxic than the other two smaller sized nanocarriers. As the
accumulation rates of the nanocarriers increase with the concentration of NPs, we could
have found a much higher number of intracellular 92.6 ± 4.4 nm drug nanocarriers if
their concentrations are the same as the 13.0 ± 3.1 and 2.4 ± 0.7 nm drug nanocarriers
(378 time higher). These results suggest size-dependent accumulation rates and efflux
function of MsbA membrane transporters and the cells could not extrude the larger NPs
out of single live cells as effectively as smaller NPs.

Characterization of the Viability of Single Cells
As reported previously, antibiotic drug nanocarriers with a diameter of 92.6 ± 4.4
nm inhibited bacterial growth in a dose-dependent manner.46 It is important to study
cellular viability as NPs could easily enter through disintegrated membrane of the dead
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cells leading to inconclusive results. Therefore, we characterized the viability of the cells
(MsbA WT) to ensure that the doses of the antibiotic drug nanocarriers (AgMUNH-Oflx
NPs), the control nanocarriers (AgMUNH2 NPs) and the pump inhibitor that we used to
probe efflux function of E. coli did not kill cells and interfere with their pump function. At
the end of each experiment, we characterized viability of the cells incubated with the
antibiotic drug nanocarriers (AgMUNH-Oflx NPs) or the control nanocarriers (AgMUNH2
NPs) throughout the duration of the experiment over 2 h using LIVE/DEAD BacLight
assay. We identify the live cells using the green SYTO9 fluorescence dye (λ max = 520
nm) which penetrates to the cells and stains cellular nucleic acids while we detect the
dead cells using red PI fluorescence dye (λmax = 610 nm) which enter only the cells with
disintegrated membrane.
Representative optical images of the cells incubated with 3.7 pM AgMUNH-Oflx
NPs in the presence (Figure 31A: a) and absence (Figure 31B: a) of orthovanadate (25
µM) over 2 h show the cells with and without NPs. Their fluorescence images illustrate
the green fluorescence but not the red fluorescence indicating that the cells are viable
(Figure 31A, B: b). We determined percentage of live and dead cells by dividing the
number of viable cells by the total number of cells. We found that more than 99 % of the
cells incubated with 3.7 pM AgMUNH-Oflx NPs in the presence and absence of
orthovanadate (25 µM) (Figure 31C) were viable. Similarly, representative optical
images of the cells incubated with 3.7 pM AgMUNH2 NPs in the presence (Figure 32A:
a) and absence (Figure 32B: a) of orthovanadate (25 µM) over 2 h show the cells with
and without NPs. The cells emitted green fluorescence but not red fluorescence
suggesting that they were viable (Figure 32A, B: b). The results show that 99 % of the
cells are alive (Figure 32C). As the cells with the NPs and orthovanadate are all alive,
the accumulation rates of the NPs in single live cells are associated with NP passive
diffusion and efflux function of the membrane transporters but not the compromised
membrane integrity due to the cell death. The findings further demonstrate that the
doses (1.85 and 3.7 pM) of the AgMUNH-Oflx NPs are suitable to use in study MDR
and efflux function of multidrug membrane transporter using drug nanocarriers in E. coli.
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Figure 31. Characterization of viability of single bacterial cells incubated with 92.6
± 4.4 nm AgMUNH-Oflx NPs using LIVE/DEAD BacLight viability and counting
assay.
In (A) and (B), representative dark field optical image (a) and fluorescence image (b) of
single bacterial cells (MsbA), incubated with 3.7 pM Ag-MUNH2-Oflx in the presence (A)
and absence (B) of the inhibitor (25 µM) over the duration of each experiment for 2 h,
show that the cells with NPs (as squared) or without NPs emit the green fluorescence (λ
max

= 520 nm) of SYTO9, indicating that cells are viable. (C) Plots of percentage of

viable cells (a) and dead cells (b) of MsbA incubated with 3.7 pM AgMUNH-Oflx with
and without the inhibitor, indicate that 99-100% of the cells are alive. Minimum 300 cells
were assayed and analyzed. The scale bar is 5 µm.
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Figure 32. Characterization of viability of single bacterial cells incubated with 92.6
± 4.4 nm AgMUNH2 NPs using LIVE/DEAD BacLight viability and counting assay.
In (A) and (B), representative dark field optical image (a) and fluorescence image (b) of
single bacterial cells (MsbA), incubated with 3.7 pM AgMUNH2 in the presence (A) and
absence (B) of the inhibitor (25 µM) over the duration of each experiment for 2 h, show
that the cells with NPs (as squared) or without NPs emit the green fluorescence (λ

max

=

520 nm) of SYTO9, indicating that cells are viable. (C) Plots of percentage of viable
cells (a) and dead cells (b) of MsbA incubated with 3.7 pM AgMUNH2 with and without
the inhibitor, indicate that 99-100% of the cells are alive. Minimum 300 cells were
assayed and analyzed. The scale bar is 5 µm.
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SUMMARY
We studied efflux kinetics of MsbA (ABC) membrane transporters in single live
cells in real time using 92.6 ± 4.4 nm antibiotic drug nanocarrier optical probes
(AgMUNH-Oflx NPs) containing 6.5 x105 Oflx molecules/NP. We found the
accumulation rates of the AgMUNH-Oflx NPs and AgMUNH2 NPs (control NPs without
Oflx) increase with the concentration of NPs indicating that the passive diffusion driven
by concentration gradients is the main mechanism for the NPs to transport into the cells,
similar to conventional pump substrates (antibiotics). We found that the pump inhibitor
(orthovanadate) affected the accumulation rates of intracellular AgMUNH-Oflx NPs and
AgMUNH2 NPs as the accumulation rates increased in the presence of orthovanadate.
Notably, we observed that the numbers of intracellular AgMUNH 2 NPs are significantly
higher than that of AgMUNH-Oflx NPs both in the presence and absence of
orthovanadate, suggesting substrate-dependent efflux function of MsbA membrane
transporters in which they could be equipped with a sensing machinery to selectively
detect, recognize and extrude toxic substrates (e.g., antibiotics and chemotherapeutic
agents). Notably, the accumulation rates and efflux kinetics of the AgMUNH-Oflx NPs
show the dependence of NP’s sizes which the accumulation rates of intracellular smalland medium-sized AgMUNH-Oflx NPs (2.4 ± 0.7 and 13.0 ± 3.1 nm) are higher than
those of the large sized AgMUNH-Oflx NPs (92.6 ± 4.4 nm). These observations might
be attributed to the higher membrane permeability and the higher concentration of the
smaller nanocarriers. In summary, this study demonstrates that single AgMUNH-Oflx
NPs and AgMUNH2 NPs can serve as excellent optical probes for study of size- and
substrate-dependent efflux function of MsbA (ABC) membrane transporters because of
their distinctive size-dependent LSPR spectra and exhibit inhibitory effects in bacterial
cells. Results from this study also suggest that multidrug membrane transporters could
have a sensing machinery to screen for toxic substrates.

Better understanding of

molecular basis of efflux mechanisms will result in a feasibility of a better drug design
that could potentially improve drug efficacy and avoid MDR in pathogenic bacterial cells,
such as E. coli.
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MATERIALS AND METHODS
Reagents and Cell Line
We purchased sodium chloride, sodium phosphate (Sigma-Aldrich), sodium
phosphate monobasic monohydrate (Sigma-Aldrich), bacto-tryptone (Sigma-Aldrich),
yeast extract (Sigma-Aldrich), orthovanadate (Sigma-Aldrich). We purchased Live/dead
backlight viability assay (Life Technologies) and Hoechst 33342 (Life Technologies).
We used all reagents as received. We used the nanopure deionized (DI) water (18 MΩ
water, Barnstead) to rinse glassware and prepare all solutions including standard LB
medium (1% tryptone peptone, 0.5% yeast extract, and 0.5% NaCl, pH = 7.2). We
purchased cell line of Escherichia coli, wt w3110 (MsbA) from Coli Genetic Stock Center
(CGSC).

Cell Culture and Preparation
We pre-cultured E. coli (MsbA) strain cells in an Erlenmeyer flask containing 10
mL of L-Broth (LB) medium (1% tryptone peptone, 0.5% yeast extract, and 0.5% NaCl,
pH = 7.2) in an incubated floor shaker (Thermo Scientific, MaxQ5000; 160 rpm, 37 °C).
After 12 h incubation, we inoculated 3 mL of pre-cultured cells into 10 mL of the LB
medium in an Erlenmeyer flask. We then incubated the flask in the shaker (160 rpm, 37
°C) for another 8 h. We harvested the cultured cells using centrifugation (Beckman
Model J2-21 Centrifuge, JA-14 rotor, at 7500 rpm, 23 °C, 10 min), washed the cells with
the PBS buffer (0.5 mM phosphate buffer, 1.5 mM NaCl, pH 7.0) three times, and finally
re-suspended the cells in the buffer. The final concentration of the cells was adjusted to
OD600 nm = 0.7 and used for the entire study.

Imaging of Single Intracellular and Extracellular NPs in Single Living Cells and
Cellular Viability Characterization
The cell suspension (OD600 nm = 0.7) containing 1.85 pM and 3.7 pM of AgMUNHOflx NPs and AgMUNH2 NPs (control NPs without ofloxacin) in the presence and
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absence of orthovanadate (25 µM) was prepared. The timer was simultaneously started
to record the incubation time as NPs were added into the cell suspension. We sampled
the mixture (1 µL) into a micro-chamber created by nail polish and imaged the cells on
18 representative locations using DFOMS equipped with a CCD camera and a digital
color camera every 25 min (7 min for the slide preparation and 18 min for imaging) for 2
h and 5 min. Imaging of the transport of single nanocarriers moving in and out of single
cells in real time using DFOMS allowed us to identify and locate positions of single NPs
simultaneously.
The design and construction is fully explained in our previous studies.9, 12-14, 25, 2830, 42-43, 58-59, 61-62, 75, 78

In particularly, our dark-field optical microscope was equipped with

a dark-field condenser (oil 1.43-1.20, Nikon), a 100x objective (Nikon Plan fluor 100x oil,
iris SL N.A. 0.5-1.3, W.D.0.20 mm), a charge coupled device (CCD) camera (Micromax,
Roper Scientific), a digital color camera (Handycam, Sony) and a multispectral imaging
system (Nuance, Cambridge Research Inc.).42-43 We have achieved high temporal
resolution up to 5 ms to continuingly image of transport of single NPs in and out of
single living cells.9, 14 However, we acquired images in every 1 min as we found that the
transport of single NPs in and out of single living cells was not a rapid process.9,

14

Thus, a temporal resolution of minutes was sufficient to study transport of single NPs in
real time.
We prepared a fresh micro-chamber every 25 min and imaged single cells for 18
representative locations. This approach allowed us to study transport of single NPs in
massive numbers of cells (1500 cells) for each sample to make data adequate for
probing the accumulation rates of bulk cells at a single cell resolution. We quantified
intracellular NPs and plotted them versus incubation time and determined the
accumulation rates (slopes of the plots) of single NPs in the cells over time.
Lastly, we characterized the viability of the cells at a single cell resolution using
LIVE/DEAD BacLight viability and counting assay at the end of each 2h-experiment.
We imaged cells in the micro-chamber using dark-field optical microscopy and epifluorescence microscopy and counted the green fluorescence cells (peak wavelength of
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fluorescence spectra of SYTO9, λmax = 520 nm) and the red fluorescence cells (peak
wavelength of fluorescence spectra of propidium iodide, λmax = 610 nm) as live and
dead cells, respectively.

Data Analysis and Statistics
Cells were imaged for eighteen representative locations of each cell suspension
incubated with 1.85 pM and 3.7 pM NPs every 25 min over 2h and 5 min. Approximately
fifteen cells were acquired in a single CCD image simultaneously. Therefore,
approximately 300 cells were imaged every 25 min and 1500 cells were studied over 2
h and 5 min for each measurement. We repeated each experiment three times. Thus,
we studied 4500 cells for each sample allowing us to gain sufficient statistics to study
efflux function of bulk cells at single cell resolution. We analyzed the numbers of
intracellular NPs in 900 cells (300 cells per each measurement) at every 25 min and
plotted them over time to determine the accumulation rates (slope of the plot) of
intracellular NPs of both AgMUNH-Oflx NPs and AgMUNH2 NPs for the cells in the
absence and presence of orthovanadate (25 µM). We determined accumulation of
intracellular NPs at 41.5 min incubation. We performed statistical analysis (2-sample ttest) using SPSS to compare means of intracellular NPs in the treated cells.
The viability of single cells was characterized at a minimum of 150 cells that were
incubated with each type of NPs after each experiment (2 h). We repeated each
measurement three times. Therefore, 450 cells were assayed for each sample.
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CHAPTER VI

CONCLUSION

This dissertation presents our development of Ag NP-based antibiotic drug
nanocarriers to serve as powerful drug delivery vehicles and as superior photostable
drug nanocarrier optical probes, aiming to improve drug efficacy and to study efflux
function of multidrug ABC membrane transporters in single live cells for a better
understanding of the molecular basis of MDR mechanisms. We have studied and found
size-dependent inhibitory effects of antibiotic drug nanocarriers against bacterial cells
(e.g., Escherichia coli). We have studied efflux kinetics of multidrug ABC membrane
transporters (MsbA) in single live E. coli cells using different sized antibiotic drug
nanocarriers. A summary of significant findings in each chapter is described below.
As described in Chapter II, we synthesized and characterized three different
sized antibiotic drug nanocarriers (AgMUNH-Oflx NPs) by functionalizing three different
sized Ag NPs (2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm) with a monolayer of AUT to
prepare AgMUNH2 NPs, followed by covalently conjugating the amine group of the
AgMUNH2 NPs with the carboxyl group of an antibiotic (ofloxacin, Oflx). We determined
the amount of conjugated Oflx molecules on each single NP (the conjugation ratios) of
2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm as 8.6x10 2, 9.4x103, and 6.5x105 molecules/NP,
respectively. We studied the dependence of inhibitory effects of free Oflx and
conjugated Oflx attached on the surface of the nanocarriers on the dose of Oflx and the
size of nanocarriers in E. coli. We found that the inhibitory effects of Oflx significantly
depend on the dose of Oflx and the size of nanocarriers. The largest nanocarriers (92.6
± 4.4 nm) show the highest inhibitory effects with the lowest MIC 50 (0.026 ± 0.003 µM)
of Oflx while the smallest nanocarriers (2.4 ± 0.7 nm) exhibit the lowest bactericidal
inhibitory with the highest MIC50 (0.314 ± 0.010 µM) of Oflx against E. coli. These
results demonstrate that the same amount of Oflx generates a substantially higher
bactericidal potency when it is carried and delivered by the larger nanocarriers. The
findings suggest that the densely loaded Oflx molecules (multivalence) enhance their
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binding affinity to the targets and the higher drug payload could raise local drug
concentrations and their bactericidal effects. Thus, an optimal size of nanocarriers is
required to create maximum inhibitory effects against pathogenic bacteria. Notably, the
inhibitory effects of drug nanocarriers are dose dependence but not linearly proportional
to their sizes indicating that an interplay among several factors, such as the
multivalence effects, their intracellular distribution (pharmacodynamics) and the
extrusion by multidrug membrane transporters could contribute to their inhibitory effects.
Therefore, we further used these antibiotic drug nanocarriers to study efflux function of
multidrug ABC (MsbA) membrane transporters in single live cells (E. coli), as presented
in Chapter III – V.
In Chapter III, we used the smallest antibiotic drug nanocarriers (2.4 ± 0.7 nm
AgMUNH-Oflx NPs) and the same sized control nanocarriers (AgMUNH2 NPs) to probe
efflux kinetics of ABC (MsbA) membrane transporters of single live E coli cells. We
developed an imaging method including DFOMS which uses LSPR spectra of single
AgMUNH-Oflx NPs and AgMUNH2 NPs to identify and track transport of single NPs in
and out of single live cells over time. We found a high dependence of the accumulation
of intracellular AgMUNH-Oflx NPs and AgMUNH2 NPs upon a presence of a pump
(ATPase) inhibitor (25 µM orthovanadate) and the concentration of NPs (0.7 and 1.4
nM). These results suggest that the NPs are substrates of MsbA transporters and more
likely enter the cells via passive diffusion, which are driven by concentration gradient
across the cellular membrane similarly to fluorescence dye (Hoechst 33342) and
conventional antibiotics. Interestingly, the accumulation of the AgMUNH2 NPs is twice
that of the AgMUNH-Oflx NPs in single live cells. These findings suggest substratedependent efflux kinetics of MsbA, showing that the efflux pumps can extrude noxious
substrates (e.g., conjugated Oflx) more effectively and rapidly out of the cells than
AgMUNH2 NPs because the AgMUNH-Oflx NPs consist of conjugated Oflx which
exhibits inhibitory effects while the AgMUNH2 NPs are biocompatible to the cells as we
reported in Chapter II. This provides an evidence that multidrug membrane transporters
might have a sensing machinery to selectively detect, recognize toxic substances (e.g.,
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antibiotics and anticancer drugs), and then extrude them out as cellular defense
mechanisms.
Furthermore, in Chapter IV, we used slightly larger antibiotic drug nanocarriers
(13.0 ± 3.1 nm AgMUNH-Oflx NPs) and the same sized control nanocarriers (AgMUNH2
NPs) to probe efflux kinetics of ABC (MsbA) membrane transporters of single live E coli
cells using DFOMS. We found that the accumulation rates and efflux kinetics depend on
the concentration of NPs, suggesting that they most likely enter the cells through
passive diffusion. Interestingly, we found that the pump inhibitor (orthovanadate) only
caused an increasing of the accumulation rate of intracellular AgMUNH-Oflx NPs. The
accumulation rates of intracellular AgMUNH2 NPs in the presence and absence of
orthovanadate are essentially the same (9 NPs/min) during the first 90 min incubation
and much higher than those of the AgMUNH-Oflx NPs at any given time points. These
results confirm the dependence of efflux function of MsbA membrane transporters on
types of substrates, and that the efflux pumps can effectively extrude harmful
substances, similarly to results previously reported in Chapter III. Moreover, we found
that the efflux pumps might be able to extrude the smaller nanocarriers (2.4 ± 0.7 nm)
more effectively than the larger nanocarriers (13.0 ± 3.1 nm) as the number of
intracellular 2.4 ± 0.7 nm AgMUNH-Oflx NPs become significantly higher than those of
13.0 ± 3.1 nm AgMUNH-Oflx NPs when the efflux pumps were blocked by the inhibitor
(p = 0.004).
Finally, as we described in Chapter V, we studied efflux kinetics of ABC (MsbA)
membrane transporters of single live E coli cells using the largest antibiotic drug
nanocarriers (92.6 ± 4.4 nm AgMUNH-Oflx NPs) and the same sized of blank control
nanocarriers (AgMUNH2 NPs). We found that the accumulation rates of intracellular
NPs and efflux kinetics of MsbA membrane transporters depend on the concentration of
NPs, suggesting that such large NPs could passively diffuse into the cells. Moreover,
the pump inhibitor (orthovanadate) interrupt efflux function of MsbA membrane
transporters leading to the increase of accumulation rates of intracellular AgMUNH-Oflx
NPs and AgMUNH2 NPs. Interestingly, similarly to the small drug nanocarriers (2.4 ± 0.7
and 13.0 ± 3.1 nm), we found that the accumulation rates of intracellular AgMUNH2 NPs

110

in the presence and absence of orthovanadate are higher than those of the AgMUNHOflx NPs, emphasizing the dependence of the accumulation rates on the type of NPs.
Notably, we found that the accumulation rates of the larger NPs (92.6 ± 4.4 nm) are
slower than those of the smaller NPs (2.4 ± 0.7 nm and 13.0 ± 3.1 nm). These findings
could be attributed to the low membrane permeability and much low concentration
gradients of 92.6 ± 4.4 nm nanocarriers. As the accumulation rates of the nanocarriers
increase with the concentration of NPs, we could have found a much higher number of
intracellular 92.6 ± 4.4 nm drug nanocarriers if their concentrations are the same as the
13.0 ± 3.1 and 2.4 ± 0.7 nm drug nanocarriers (378 time higher). These results suggest
size-dependent accumulation rates and efflux function of MsbA membrane transporters
and the cells could not extrude the larger NPs out of single live cells as effectively as
the smaller NPs.
Taken together, this dissertation demonstrated that Ag NPs can serve as not only
powerful drug nanocarriers, but also photostable size-dependent optical imaging probes
for the study of ABC (MsbA) transporters in single live cells (E. coli). Drug therapeutic
effects increase substantially when they are delivered by the larger nanocarriers. We
can study the efflux function of multidrug ABC membrane transporters using the drug
nanocarriers as superior photostable plasmonic optical probes. We found that the
smaller nanocarriers could be effectively extrude out of the cells by the ABC (MsbA)
membrane transporters more effectively than the larger nanocarriers, and therefore,
they are less toxic than the larger nanocarriers, making them well suited as excellent
imaging probes. In contrast, the larger nanocarriers show higher potent inhibitory effects
than the smaller nanocarriers, enabling them to server as powerful drug delivery
vehicles. All these findings offer a possibility of designing antibiotic drug nanocarriers
that could generate the most potent bactericidal effects and overcome MDR.
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APPENDIX

This dissertation follows the procedures and guidelines how to work safely and
handle biohazard materials in the protocol number 16-009 approved by the Institutional
Biosafety Committee. Personnel who works with biohazard materials such as bacteria
and nanoparticles must wear cloth lab coats, disposable gloves and safety goggles.
Appropriate personal clothing is required in all laboratories. Long pants and closed
toed shoes are required. Hand washing facilities are provided in all labs and hand
washing must be performed after handling bacterial cells and nanomaterials. All
solutions are disposed of as hazardous waste following established guidelines of the
Environmental Health and Safety Office. All personnel must complete all applicable
CITI trainings and pass all the requirements.
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